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Background and aims 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. In Finland, 
3,538 new cases were diagnosed in 2018. While the incidence of CRC is generally increasing, 
the mortality rates have been decreasing in many countries due to reduced risk factors, 
screening, and advances in pathological diagnostics, surgical techniques, and oncological 
treatments. Approximately half of all CRC patients develop metastatic disease, and up to 
75% of the metastases are diagnosed in the liver. Contrary to many other cancers, even 
metastatic CRC may be treated curatively, if the metastases are limited and can be surgically 
removed. Currently, approximately 20–30% of the liver metastases can be resected, but over 
50% of the patients develop recurrent disease afterwards. Estimating the prognosis after 
liver resection is of utmost importance, as identifying the patients with a high risk of 
recurrence enables adjusting the surgical and oncological treatments accordingly, and thus, 
improving postoperative survival.  
The aim of this thesis was to evaluate the prognostic significance of 12 biomarkers measured 
in serum, plasma, and tissue samples of both the primary colorectal tumors and the liver 
metastases in patients undergoing curative-intent liver resection for colorectal metastases.  
 
Materials and methods 
Altogether 442 patients who underwent liver resection for colorectal metastases at the 
Helsinki University Hospital between the years 1998 and 2013 were included in this thesis. 
The four studies are based on the serum samples from all patients (I–III), the plasma samples 
from a subset of 168 patients (I), and the tumor tissue specimens from a subset of 111 
patients who had both primary colorectal tumors and liver metastases operated on at the 
Helsinki and Uusimaa Hospital District (III and IV). Serum and plasma samples were drawn 
before liver resection and approximately 3 months afterwards. Tissue specimens included 
samples of both the primary colorectal tumors and the liver metastases.  
The concentrations of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), 
and C-reactive protein (CRP) were retrieved from clinical records (I and II). Those of human 
chorionic gonadotropin β (hCGβ) in plasma, tumor-associated trypsin inhibitor (TATI) in 
plasma, and matrix metalloproteinase-8 (MMP-8) in serum were measured by time-resolved 
immunofluorometric assay (IFMA) methods (I and III). YKL-40 (chitinase-3-like protein-1, 
CHI3L1), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), and myeloperoxidase 
(MPO) were determined in the serum samples using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits (II and III). The expressions of matrix metalloproteinase-2 
(MMP-2), MMP-8, MMP-9, and transketolase-like protein 1 (TKTL1) were analyzed in the 
immunohistochemically stained tumor tissue samples. Clinical data were retrieved from 
patient records, and information about the dates of death was obtained from the Central 
Statistical Office of Finland. Survival analyses were performed using the Kaplan-Meier 





Postoperatively elevated CEA (>5.0 µg/l) was found to predict shorter disease-free/relapse-
free survival (DFS/RFS) and overall survival (OS). Preoperatively elevated CEA associated only 
with shorter OS (I and II). Pre- and postoperatively elevated CA19-9 (>26 or >37 kU/l) 
indicated shorter DFS/RFS and OS, but postoperatively the additional value compared to CEA 
was limited (I and II).  
Preoperatively elevated TATI (>13 µg/l) associated with poor 3-year DFS after liver resection 
in the whole patient cohort, and especially in patients with synchronous liver metastases. 
Postoperatively elevated hCGβ (>1.0 pmol/l) associated with poor 3-year OS in the whole 
cohort, and it was a sign of impaired prognosis especially among male patients and those 
with primary rectal tumors (I).  
A biomarker panel comprising YKL-40, IL-6, CRP, CEA, and CA19-9 was found prognostic, as 
patients with 2–5 elevated biomarkers pre- or postoperatively were at an increased risk of 
recurrence and death after liver resection (II).  
High expression of MMP-9 in primary colorectal tumors and high preoperative MPO in 
serum indicated improved prognosis after liver resection. Additionally, the prognostic 
significance of these biomarkers, as well as that of MMP-2 and MMP-8, were found to 
depend on the clinical characteristics of the patients (III).  
High TKTL1 expression in the primary colorectal tumors associated with impaired prognosis 
after liver resection in patients with synchronous liver metastases, but with improved 
prognosis in those with metachronous metastases. Similar tendencies were observed 
concerning the expression in the liver metastases (IV). 
 
Conclusions 
In conclusion, CEA is a useful prognostic biomarker for most patients undergoing liver 
resection for colorectal metastases. However, about half of the patients do not have 
elevated serum levels of CEA despite of metastatic disease, and they may benefit from 
measuring other biomarkers. A biomarker panel comprising YKL-40, IL-6, CRP, CEA, and 
CA19-9 could be used to identify patients at a high risk of recurrence after liver resection 
already before the operation. Especially preoperative CA19-9 and YKL-40 also had 
independent prognostic value.  
MMP-9 and TKTL1 in primary colorectal tumors may serve for assessing whether the 
patients benefit from liver resection or need more aggressive chemotherapy, but the 
synchronicity of the liver metastases should be taken into consideration. Elevated 
preoperative serum levels of MPO indicated improved prognosis, and low levels implied a 
high risk of recurrence. The prognostic value of MMP-2, MMP-8, MMP-9, and MPO varied 
according to clinical factors, possibly due to immunological or hormonal mechanisms. 
The investigated biomarkers provide new information about CRC with liver metastases and 
increase our understanding of the disease. They help us define the prognosis after liver 
resection and adjust the individual patients’ treatment accordingly. Thus, they contribute to 







Tausta ja tavoitteet 
Paksu- ja peräsuolisyöpiä (kolorektaalisyöpiä) todetaan kolmanneksi eniten kaikista 
maailman syövistä. Suomessa uusia tautitapauksia todettiin vuonna 2018 yhteensä 3 538. 
Kolorektaalisyövän ilmaantuvuus on laajalti lisääntynyt, mutta toisaalta kuolleisuus on 
vähentynyt, minkä katsotaan johtuvan riskitekijöiden vähenemisestä, seulonnasta sekä 
patologisen diagnostiikan, kirurgisten menetelmien ja onkologisten hoitomahdollisuuksien 
kehittymisestä. Noin puolelle kolorektaalisyöpäpotilaista ilmaantuu etäpesäkkeitä 
(metastaaseja), joista jopa 75 % todetaan maksassa. Toisin kuin monissa muissa syövissä, 
kolorektaalisyövässä myös levinneestä taudista parantuminen on mahdollista, mikäli 
metastaaseja on rajallinen määrä ja ne on mahdollista poistaa kirurgisesti. Nykyisin jopa 20–
30 % maksametastaaseista onnistutaan leikkaamaan (resekoimaan), mutta yli 50 %:lla 
potilaista tauti uusii myöhemmin. Leikkauksen jälkeisen ennusteen arvioiminen on 
huomattavan tärkeää, sillä tunnistamalla potilaat, joilla uusimisriski on suuri, kirurginen ja 
onkologinen hoito voidaan suunnitella yksilöllisesti ja siten parantaa ennustetta.  
Tämän väitöskirjan tavoitteena oli arvioida 12:n merkkiaineen ennusteellista arvoa potilailla, 
joille oli tehty maksaresektio parantavalla hoitotavoitteella. Merkkiaineita tutkittiin 
seerumista, plasmasta sekä primääreistä suolikasvaimista ja maksametastaaseista otetuista 
kudosnäytteistä.  
 
Aineisto ja menetelmät 
Tämän väitöskirjan aineistoon kuuluu yhteensä 442 potilasta, joilta leikattiin 
kolorektaalisyövän maksametastaasit Helsingin yliopistollisessa keskussairaalassa vuosina 
1998–2013. Kirjan neljän osatyön pohja-aineistona olivat seeruminäytteet, jotka otettiin 
kaikilta potilailta (I–III), plasmanäytteet 168:n potilaan alaryhmältä (I) sekä 
kasvainkudosnäytteet 111:ltä potilaalta, joilta oli leikattu sekä primääri suolikasvain että 
maksametastaasit Helsingin ja Uudenmaan sairaanhoitopiirissä (III ja IV).   Seerumi- ja 
plasmanäytteet otettiin ennen maksaresektiota (preoperatiivisesti) ja noin kolme kuukautta 
sen jälkeen (postoperatiivisesti). Kudosnäytteet otettiin sekä suolikasvaimista että 
maksametastaaseista.  
Tiedot karsinoembryonaalisen antigeenin (CEA), karbohydraattiantigeeni 19-9:n (CA19-9) ja 
C-reaktiivisen proteiinin (CRP) pitoisuuksista haettiin potilastietojärjestelmistä (I ja II). 
Plasman koriongonadotropiinin β-alayksikön (hCGβ) ja tuumoriin liittyvän trypsiinin estäjän 
(TATI) sekä seerumin matriksin metalloproteinaasin 8 (MMP-8) määritykset tehtiin käyttäen 
immunofluorometrisiä menetelmiä (IFMA) (I ja III). YKL-40:n (kitinaasi-3:n kaltainen proteiini 
1, CHI3L1), interleukiini 6:n (IL-6), matriksin metalloproteinaasin 9 (MMP-9) ja 
myeloperoksidaasin (MPO) pitoisuudet määritettiin seeruminäytteistä entsyymivälitteisellä 
immunosorbenttimenetelmällä (ELISA) (II ja III).  Matriksin metalloproteinaasin 2 (MMP-2), 
MMP-8:n, MMP-9:n ja transketolaasin kaltaisen proteiinin 1 (TKTL1) ilmentyminen 
analysoitiin kasvainkudosnäytteistä (III ja IV). Kliiniset tiedot haettiin 
potilastietojärjestelmistä ja tiedot kuolinpäivistä Tilastokeskukselta. Elossaoloanalyysit 






Maksaresektion jälkeen suurentunut CEA-pitoisuus (> 5,0 µg/l) ennusti lyhentyneitä 
tautivapaata ja kokonaiselossaoloaikaa sekä leikkausta edeltävästi suurentunut CEA 
lyhentynyttä kokonaiselossaoloaikaa (I ja II). Resektiota ennen tai sen jälkeen suurentuneet 
CA19-9-pitoisuudet (> 26 tai > 37 kU/l) yhdistyivät lyhentyneisiin tautivapaaseen ja 
kokonaiselossaoloaikaan, mutta postoperatiivisesti CA19-9:n lisäarvo suhteessa CEA:han oli 
varsin vähäinen (I ja II).  
Preoperatiivisesti suurentunut TATI (> 13 µg/l) yhdistyi huonontuneeseen tautivapaan 
elossaoloajan ennusteeseen kaikilla potilailla ja erityisesti niillä, joiden maksametastaasit 
todettiin enintään kuusi kuukautta suolileikkauksen jälkeen (synkroniset maksametastaasit). 
Postoperatiivisesti suurentunut hCGβ (> 1,0 pmol/l) ennusti huonontunutta 
kokonaiselossaoloaikaa kolmen vuoden aikana maksaresektion jälkeen kaikilla potilailla, ja 
lisäksi se oli huonon ennusteen merkki varsinkin miespotilailla ja peräsuolisyövässä (I).  
YKL-40:n, IL-6:n, CRP:n, CEA:n ja CA19-9:n osalta todettiin, että taudin uusimisen ja 
kuoleman riski oli selvästi lisääntynyt potilailla, joilla kyseisistä merkkiaineista vähintään 
kahden pitoisuudet olivat suurentuneet pre- tai postoperatiivisesti (II).  
MMP-9:n voimakas ilmentyminen suolikasvaimissa ja suuri MPO-pitoisuus seerumissa 
yhdistyivät hyvään ennusteeseen maksaresektion jälkeen. Lisäksi havaittiin, että näiden 
merkkiaineiden sekä MMP-2:n ja MMP-8:n ennusteelliseen arvoon vaikuttivat potilaiden 
kliiniset ominaisuudet ja taudinkuva (III).  
TKTL1:n voimakas ilmentyminen suolikasvaimissa ja maksametastaaseissa yhdistyi 
huonontuneeseen ennusteeseen potilailla, joilla oli synkroniset maksametastaasit. Sen sijaan 
potilailla, joilla oli myöhemmin ilmaantuneet (metakroniset) metastaasit, voimakas 
ilmentyminen oli paremman ennusteen merkki (IV).  
 
Yhteenveto 
Yhteenvetona CEA:n todettiin olevan käyttökelpoinen merkkiaine suurella osalla potilaista, 
joilta leikataan kolorektaalisyövän maksametastaasit. Noin puolella potilaista kyseisen 
merkkiaineen pitoisuudet eivät kuitenkaan suurene edes levinneessä taudissa, ja heidän 
kohdallaan olisi hyvä harkita muiden merkkiaineiden käyttämistä. YKL-40:n, IL-6:n, CRP:n, 
CEA:n ja CA19-9:n muodostaman merkkiainepaneelin avulla voitaisiin tunnistaa jo ennen 
maksaresektiota potilaat, joilla taudin uusimisriski on lisääntynyt. Leikkausta edeltävästi 
varsinkin CA19-9 ja YKL-40 olivat ennusteellisia myös itsenäisesti.  
Suolikasvainten MMP-9- ja TKTL1-ilmentymistä voitaisiin käyttää sen arvioimiseen, 
hyötyvätkö potilaat enemmän maksaresektiosta vai tehokkaammasta onkologisesta 
hoidosta. Tähän vaikuttaa maksametastaasien ilmaantumisaika. Seerumin suuren MPO-
pitoisuuden havaittiin olevan hyvän ennusteen ja vähäisen pitoisuuden vastaavasti huonon 
ennusteen merkki. MMP-2:n, MMP-8:n, MMP-9:n ja MPO:n ennusteellinen arvo vaihteli 
potilaiden eri alaryhmissä, mikä saattaa liittyä immunologisiin ja hormonaalisiin 
säätelymekanismeihin.  
Tutkitut merkkiaineet antavat uutta tietoa maksaan levinneestä kolorektaalisyövästä ja 
lisäävät ymmärrystämme kyseisestä taudista. Niiden avulla ennustetta maksaresektion 
jälkeen voidaan arvioida aiempaa paremmin, ja yksittäisten potilaiden hoitoa voidaan 
muokata sen mukaisesti. Täten nämä merkkiaineet edesauttavat parhaan mahdollisen 








18qLOH Chromosome 18q loss of heterozygosity 
AFAP Attenuated familial adenomatous polyposis 
ALPPS Associating Liver Partition and Portal vein ligation for Staged hepatectomy 
APC Adenomatous Polyposis Coli (gene) 
BRAF Murine sarcoma viral (v-raf) oncogene homolog B1, B-Raf proto-oncogene 
CA19-9 Carbohydrate antigen 19-9 
CEA Carcinoembryonic antigen 
cfDNA Cell-free DNA 
CGI CpG island 
CHI3L1 Chitinase-like protein-1 (YKL-40) 
CIMP CpG island methylator phenotype 
CIN Chromosomal instability 
CME Complete mesocolic excision 
CRC Colorectal cancer 
CRM Circumferential resection margin 
CRP C-reactive protein 
CT Computed tomography 
CTC Circulating tumor cell 
ctDNA Circulating tumor DNA (tumor-derived fragmented DNA) 
CV Coefficient of variation 
DFS Disease-free survival 
DNA Deoxyribonucleic acid 
DPD Dihydropyrimidine dehydrogenase 
DTPA Diethylenetriaminepentaacetic acid 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
ENV EnVision (DAKO Real EnVision / Real EnVision Flex) 
FAP Familial adenomatous polyposis 
FCCTX Familial colorectal cancer type X 
FLR Future liver remnant 
FSH Follicle-stimulating hormone 
GTPase Guanosine triphosphatase 
HCC Hepatocellular cancer 
hCG Human chorionic gonadotropin 
hCGβ Free β subunit of human chorionic gonadotropin 
HCl Hydrochloric acid 
HE Hematoxylin-eosin 
HNPCC Hereditary non-polyposis colorectal cancer 
HOCl Hypochlorous acid 
HRP Horseradish peroxidase 
hsCRP high-sensitivity CRP 
IEC Intestinal epithelial cell 
IFMA Immunofluorometric assay  
IL-6 Interleukin-6 
IQR Interquartile range 
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JPS Juvenile polyposis syndrome 
HRAS Harvey rat sarcoma viral oncogene 
KRAS Kirsten rat sarcoma viral oncogene 
LH Luteinizing hormone 
LOH Loss of heterozygosity 
LS Lynch syndrome 
MAC Mucinous adenocarcinoma 
MAP MutYH-associated polyposis 
MAPK Mitogen-activated protein kinase 
MSI Microsatellite instability 
MDT Multidisciplinary team 
MMP-2 Matrix metalloproteinase-2 (gelatinase-A) 
MMP-8 Matrix metalloproteinase-8 (collagenase-2, neutrophil collagenase) 
MMP-9 Matrix metalloproteinase-9 (gelatinase-B) 
MMR Mismatch repair 
MPO Myeloperoxidase 
MRF Mesorectal fascia 
MRI Magnetic resonance imaging 
NRAS Neuroblastoma RAS viral oncogene homolog 
NAP NTHL1-associated polyposis 
OS Overall survival 
PD1 Programmed cell death 1 
PET Positron emission tomography 
PHTS PTEN hamartoma tumor syndrome 
PJS Peutz-Jeghers syndrome 
PlGF Placental growth factor 
PPP Pentose phosphate pathway 
PSTI Pancreatic secretory trypsin-inhibitor (SPINK1, TATI) 
RAGE Receptor for advanced glycation end products 
RAS Rat sarcoma (referring to the RAS gene family) 
RFA Radiofrequency ablation 
RFS Relapse-free survival 
RNA Ribonucleic acid 
ROC Receiver-operating characteristic 
SBRT Stereotactic body radiotherapy 
SI-CLP Stabilin-1 interacting chitinase-like protein 
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TGFβ Transforming growth factor β 
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TKTL1 Transketolase-like protein 1 
TMA Tissue microarray 
TME Total mesorectal excision 
TNM Tumor Node Metastasis (classification of malignant tumors) 
TSH1 Two-stage hepatectomy 
TSH2 Thyroid-stimulating hormone  
VEGF Vascular endothelial growth factor 






Colorectal cancer (CRC) is the third most commonly diagnosed malignancy in the world and 
the second-leading cause of cancer death, accounting for over 800,000 deaths every year 
(Bray et al., 2018). The incidence of CRC has been increasing over the last decades, which is 
linked to the rapid adoption of the Western lifestyle around the world. This includes changes 
in diet, obesity, and lack of physical activity, which all increase the risk of cancer. On the 
other hand, the treatment of CRC has improved substantially, partly due to significant 
research findings concerning the development and characteristics of the disease. Advances 
in screening, diagnostics, surgical techniques, and individualized oncological treatment 
options have led to an improved prognosis in the affected patients, also in metastatic stage 
IV cancer.  
 
It has been estimated that approximately half of all CRC patients develop metastases, the 
majority of which are diagnosed in the liver (up to 75%) and the lungs (up to 30%) (Sorbye et 
al., 2007). Contradictory to several other cancers, the isolated metastases of CRC can 
nowadays quite often be operated on and even cure attained. As the liver is the most 
common metastatic site, interest is focused on the liver resections and their results. It has 
become obvious that patient selection according to specified characteristics is a major 
determiner of the outcome after resection. Despite of the advances in surgical techniques 
and more efficient perioperative chemotherapy, about half of the patients experience 
recurrence postoperatively. Thus, identifying the patients at a high risk of recurrence after 
liver resection has become a cornerstone of all treatment planning.  
 
Several prognostic biomarkers have been studied over the years including antigens, 
enzymes, and hormones produced or induced by the tumor tissue. It is thought that the 
occurrence of these biomarkers in the circulation signals existing cancer that is not 
detectable by other means but may generate recurrent disease at a later time, and their 
expressions in the tumor tissue may reveal crucial information about the cancer’s invasive 
and metastatic potential.  
 
Currently, knowledge of the characteristics of the cancer itself and the cell-level mechanisms 
that enable tumor growth, invasion, and metastasis is continuously increasing. Six hallmarks 
of cancer have been identified: sustaining proliferative signaling; evading growth 
suppressors; activating invasion and metastasis; enabling replicative immortality; inducing 
angiogenesis; and resisting cell death (Hanahan and Weinberg, 2011). Inflammation creates 
a cellular environment that favors tumor invasion and metastasis through various 
mechanisms. Chronic inflammation has been linked to impaired prognosis in several 
malignancies including CRC (Nasr et al., 2018), and thus, it has been suggested that detecting 
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underlying inflammation in patients with colorectal liver metastases might help estimate the 
course of the disease.  
 
Yet another aspect are the cell-level mechanisms contributing to the invasive ability of the 
cancer. Detecting tumor-related factors that signal more aggressive behavior would help 
adjust the patients’ treatment accordingly. These factors include proteins that contribute to 
the metabolism of the cancer cells or their invasive capabilities, and hence, enable 
aggressive growth.  
 
In this thesis, altogether 12 potentially prognostic biomarkers were analyzed in the serum, 
plasma, and tumor tissue of patients undergoing liver resection for colorectal metastases. 
The associations of the biomarkers with disease-free (DFS) or relapse-free survival (RFS) and 
overall survival (OS) after liver resection were studied in order to identify the patients who 
are at a high risk of recurrence or death. Important new information was also obtained 
concerning the concentrations and expressions of these biomarkers in CRC with liver 
metastases, and this increases knowledge of the characteristics of the disease. Estimating 
the risk of recurrence after liver resection will help adjust the oncological treatments 
individually and choose the optimal time point for the surgical interventions. In addition, 
when the characteristics of the cancer and the estimated course of the disease can be 
evaluated, the optimal treatment options may be identified and thus, the best possible care 










Colorectal cancer (CRC) is the third most commonly diagnosed malignancy in the whole 
world (Torre et al., 2015) (Table 1). The deaths caused by CRC have been increasing during 
the last years: in 2012, it was fourth most common cause of cancer death worldwide, and in 
2018, already the second (Bray et al., 2018). The new cases and deaths are expected to 
increase by as much as 60% by the year 2030, raising the global burden of this disease 
significantly. In Finland, CRC was the third most commonly diagnosed cancer and the second 
leading cause of cancer death in 2018, and its incidence has been increasing in accordance 
with the global trends: in 2004–2008, the incidence was 48.0/100,000/year, but in 2014–
2018, already 60.9/100,000 (Syöpärekisteri, 2018) (Finnish Cancer Registry).  
 
The incidence and mortality of CRC are strongly linked to the socioeconomic status of 
different countries and areas around the world. CRC was earlier considered a disease of the 
developed countries, but in the last years, the rates have been rapidly increasing especially 
in the less developed countries (Center et al., 2009, Arnold et al., 2017). These recent 
changes are supposedly due to the adoption of the Western lifestyle, as it brings along the 
generally known risk factors for CRC including obesity, low-fiber diet, physical inactivity, and 
smoking (Giovannucci, 2002, Botteri et al., 2008). On the other hand, in several developed 
countries, stabilizing or even declining trends in incidence and mortality have been reported 
(Torre et al., 2015). These declining trends presumably reflect the progress in early detection 





2.1 General risk factors 
 
Colorectal cancer develops as a result of genetic, environmental, and lifestyle factors. 
Commonly known risk factors are physical inactivity, obesity, excess intake of red meat, low-
fiber diet, smoking, and high consumption of alcohol (Giovannucci, 2002, Baena and Salinas, 
2015, Cho et al., 2019).  
Chronic inflammation has been identified as a significant cancer-promoting factor (Hanahan 
and Weinberg, 2011, Nasr et al., 2018). In the intestine, changes in the microbiome are 
suggested to influence the development of CRC through enhancing the release of bacterial 
toxins, the disruption of epithelial barrier, and the production of carcinogenic metabolites 
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(Lucas et al., 2017). Considering this, it is understandable that nutrition affects the risk of 
CRC by bringing along bacteria and other compounds into the intestine. The relationship of 
inflammation and cancer is, however, controversial: while the bacterial microbiota induces 
cancer-promoting low-grade inflammation, the innate immune activation is needed for anti-
cancer immune responses (Schwabe and Jobin, 2013).  
 
 
Table 1. The 5 most commonly diagnosed malignancies and the 5 leading causes of cancer 
death in the world and in Finland. Global estimates and Finnish statistics for the year 2018. 
Non-melanoma skin cancer excluded. 
Cancer Total (N) Males (n) Females (n) 
Cancer incidence 
World 18,078,957 9,456,418 8,622,539 
Lung 2,093,876 1,368,524 725,352 
Breast 2,088,849 (not reported) 2,088,849 
Colorectal 1,800,977 1,006,019 794,958 
Prostate 1,276,106 1,276,106 - 
Stomach 1,033,701 683,754 349,947 
Finland 34,372 17,836 16,536 
Prostate 5,016 5,016 - 
Breast 4,934 33 4,967 
Colorectal 3,538 1,865 1,673 
Lung and trachea 2,745 1,710 1,035 
Mature B-cell lymphomas 1,964 1,083 881 
Cancer mortality 
World 9,555,027 5,385,640 4,169,387 
Lung 1,761,007 1,184,947 576,060 
Colorectal 861,663 474,606 387,057 
Stomach 782,685 513,555 269,130 
Liver 781,631 548,375 233,256 
Breast 626,679 (not reported) 626,679 
Finland 12,730 6,803 5,927 
Lung and trachea 2,285 1,473 812 
Colorectal 1,293 682 611 
Pancreatic 1,268 633 635 
Prostate 914 914 - 
Breast 878 5 873 





2.2 Hereditary colorectal cancer 
 
Approximately 10% of colorectal cancers develop due to inherited mutations in cancer-
predisposing genes (Lucas et al., 2017). The most common of these conditions is the Lynch 
syndrome (LS), earlier called hereditary non-polyposis colorectal cancer (HNPCC), which 
causes approximately 2–5% of all diagnosed CRCs (Patel and Ahnen, 2012, Mecklin, 1989). 
The prevalence of LS has been shown to be approximately 0.2% in Finland (Mecklin, 1987), 
0.4% (1:226) in Iceland (Haraldsdottir et al., 2017), and in the United States, the estimated 
population incidence is 1:370 (Hampel et al., 2005).  
LS is primarily caused by mutations in four genes of the DNA mismatch repair (MMR) system 
(MLH1, MSH2, MSH6, and PMS2), and it is inherited in an autosomal dominant pattern 
(Mecklin et al., 1995, Boland et al., 2018). However, LS may also be caused by mutations that 
affect a MMR gene, that is, those in adjacent genes or in the DNA methylation system 
(Peltomäki, 2016, Morak et al., 2011). The patients with LS have a 50–80% lifetime risk of 
developing CRC (Patel and Ahnen, 2012) depending on the precise mutational status. In 
addition, they have an increased risk of endometrial and ovarian cancer. 
 
The second most common inherited syndrome is familial adenomatous polyposis (FAP), 
which lies behind approximately 1% of all CRCs. It is a rare condition with an estimated 
prevalence of 1–9/100,000. It is caused by mutations in the Adenomatous Polyposis Coli 
(APC) gene, and the inheritance pattern is autosomal dominant. Typically, patients with FAP 
develop hundreds of thousands of colonic adenomas already in adolescence, which then 
develop into cancer at an average age of 39 years. The lifetime risk for CRC is practically 
100%, and the only effective way of preventing CRC is surgical colectomy (Patel and Ahnen, 
2012). However, also extracolonic manifestations of the condition increase mortality. 
Attenuated FAP (AFAP) is a less severe form of FAP inherited in a similar manner. 
In addition, there are other hereditary polyposis syndromes that are inherited in an 
autosomal recessive pattern. These include MutYH-associated polyposis (MAP), NTHL1-
associated (NAP), and MSH3-associated polyposes (Terradas et al., 2019). Other syndromes 
include Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), familial colorectal 
cancer type X (FCCTX), and PTEN hamartoma tumor syndrome (PHTS) (Patel and Ahnen, 







3.1 Development of colorectal cancer 
 
The development of colorectal cancer occurs within the intestinal mucosa either via a 
conventional adenoma–carcinoma sequence or a serrated pathway (Pino and Chung, 2010, 
Mäkinen, 2007). The development begins with the transformation of the normal epithelial 
cells of the mucosa into hyperproliferative intestinal epithelial cells (IECs), which form 
pedunculated or serrated polyps (Simon, 2016). The former are so-called traditional 
adenomas, and the latter can be further divided into hyperplastic polyps, sessile serrated 
lesions (SSLs), and traditional serrated adenomas/polyps (Pai et al., 2019, Mäkinen et al., 
2001, De Palma et al., 2019). CRCs originating from serrated lesions form a distinct subtype 
of the disease and constitute at least 15% of all cases.  
The polyps themselves are benign, but as the IECs proliferate, they accumulate genetic 
mutations and, with time, acquire the ability to invade the submucosa. This series of events 
gradually leads to disseminating malignant tumors, in which cells are able to grow and divide 
without limitations (Lucas et al., 2017). The process usually takes years, but cancer can also 
develop in a significantly shorter time, especially in predisposing conditions such as 
hereditary polyposis syndromes.  
 
The malignant transformation of the polyps requires at least seven distinct mutations in 
different genes (Fearon and Vogelstein, 1990). These include those in the APC gene, the 
KRAS gene, transforming growth factor β (TGF-β), PIK3CA, and TP53 genes. It has been 
estimated that an average colorectal cancer comprises up to 80 mutations (Wood et al., 
2007). Several proteins, metabolites, toxins, and other carcinogenic compounds can 
contribute to these or affect the normal cell cycle in other ways. In hereditary CRC, the 
predisposing mutations that inexorably lead to cancer are inherited.  
Cells must have a certain degree of intrinsic genomic instability before they can acquire 
sufficiently of mutations to develop into cancer cells. In sporadic CRC, three major types of 
genetic instability pathways have been described: chromosomal instability (CIN), 
microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) pathway. These 
three pathways are not exclusive, and a tumor can exhibit overlapping features (Pino and 
Chung, 2010).  
 
The CIN pathway accounts for an estimated 65–70% of the sporadic CRCs (Pino and Chung, 
2010).  In CIN-positive tumors, whole chromosomes or large portions of them are gained or 
lost at an accelerated rate, which leads to an imbalance in the chromosome number, 
genomic amplifications, and a high frequency of loss of heterozygosity (LOH) in the cells. 
These features are associated with the accumulation of mutations in tumor suppressor 




MSI accounts for the development of approximately 15–20% of sporadic CRCs (Hu et al., 
2020). Microsatellites are short, repetitive DNA sequences located in both the coding and 
non-coding regions of the human genome. These repetitive sequences are prone to 
replication errors, which are normally repaired by mismatch repair (MMR) genes. 
Deficiencies in the MMR system lead to increased additional mutations and a mutator 
phenotype, which is known as microsatellite instability (MSI). MSI is usually caused by 
methylation of the promoter region of the MLH1 gene or, in 2–3% of CRCs, mutations in the 
MMR system genes MLH1, MSH2, MSH6, and PMS2 (Lee and Chu, 2018, Muzny et al., 2012). 
 
CpG islands (CGIs) are short DNA sequences rich in the CpG dinucleotide (cytosine followed 
by guanine) and can be found in approximately half of all human genes. Aberrant 
methylation of cytosine within the CGIs causes loss of gene expression, including inactivation 
of the MLH1 gene, which is the primary cause of MSI (Kane et al., 1997, Toyota et al., 1999). 
Thus, hypermethylation of the CGIs and MSI often occur concurrently. The CGI methylator 
phenotype is also closely associated with BRAF mutations (Weisenberger et al., 2006). 
 
 
3.2 Histological subtypes 
 
Of all diagnosed CRCs, the majority are adenocarcinomas, 10–15% serrated 
adenocarcinomas, 10–15% mucinous adenocarcinomas (MACs), and approximately 1% 
signet ring cell carcinomas and 1% medullary carcinomas (Hugen et al., 2014, Nitsche et al., 
2013, Mäkinen, 2007). MAC is characterized by abundant extracellular mucin, which covers 
at least 50% of the tumor volume (Luo et al., 2019), and signet ring cell carcinoma is a MAC 
with more than 50% of a signet ring cell component (Song et al., 2019). The prognosis of 
MAC compared to adenocarcinoma is debatable, but signet ring cell carcinoma has been 
associated with worse clinical outcome (Song et al., 2019). In addition to these subtypes, less 
common forms of CRC exist, such as small cell carcinoma, squamous cell carcinoma, 
adenosquamous carcinoma, and undifferentiated carcinoma (WHO, 2019).  
 
 
3.3 Differences between proximal and distal colon 
 
Over the last years, several studies have shown that the tumors of the proximal (right) and 
distal (left) colon differ from each other in terms of biological and molecular characteristics. 
During the embryonic development, the proximal colon is derived from the midgut and the 
distal colorectum from the hindgut. These parts are joined together at the distal third of the 
transverse colon, and they have separate blood supplies, innervations, and lymphatic 
drainages (Boeckx et al., 2017, Lee et al., 2015, Missiaglia et al., 2014). Right-sided tumors 
are less frequent and more commonly diagnosed in females. They are typically serrated 
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adenocarcinomas, BRAF-mutated, microsatellite unstable, and of CGI methylator phenotype 
(Yamauchi et al., 2012). In addition, they are typically diagnosed at a later stage, associate 
with worse prognosis than left-sided tumors, and are insensitive to anti-epidermal growth 
factor receptor (EGFR) therapies (Tejpar et al., 2017).  
 
 
3.4 Invasion and metastasis 
 
The malignant colorectal tumors first invade through the layers of the intestinal wall into 
pericolic or perirectal tissues, and then further into the visceral peritoneum and adjacent 
tissues and organs (Figure 1). Submucosal lymphatic invasion has been shown to be the 
strongest predictor of lymph node metastasis (Ishii et al., 2009, Wada et al., 2015), while 
venous invasion, in particular, predicts distant metastasis (Suzuki et al., 2009). In addition, 
perineural invasion (Liebig et al., 2009) and tumor budding – the presence of single tumor 
cells or clusters of ≤4 tumor cells at the invasive margin of the tumor (Lugli et al., 2017) – 
indicate metastasis and impaired survival (Brockmoeller and West, 2019, Suzuki et al., 2009).  
 
There are several factors that affect the tumor cells’ ability to invade the adjacent tissues 
and to metastasize. In the last couple of decades, the role of tumor-associated inflammation 
has become more and more obvious. The infiltration of inflammatory cells has been found to 
promote tumor progression, as they contribute to the production of bioactive molecules 
that facilitate angiogenesis, invasion, and metastasis (Hanahan and Weinberg, 2011). Both 
tumor-antagonizing and tumor-promoting inflammatory cells can be found in basically all 
neoplastic lesions. However, the actions of those that are tumor-suppressing (cytotoxic) are 
typically inhibited by other immunosuppressive cells or by other mechanisms (Mougiakakos 
et al., 2010, Ostrand-Rosenberg and Sinha, 2009).  
 
CRC metastasizes usually first to the liver and the lungs, which is most probably due to the 









Approximately two-thirds of patients diagnosed with CRC have at least one abnormal 
symptom within the months before diagnosis (Cleary et al., 2007). The symptoms develop 
gradually, which typically leads to delayed examinations and diagnosis. The typical 
symptoms include rectal bleeding, diarrhea or constipation, abdominal pain, and loss of 
weight (Hamilton et al., 2005). Rectal bleeding may cause anemia and, subsequently, fatigue 
and cardiac symptoms. If the disease has metastasized, more distinctive symptoms may 
arise, such as loss of appetite, fever, and symptoms from the specific metastatic sites. 
However, even metastatic disease can be diagnosed by coincidence with no previous 
symptoms, or the symptoms can be inconspicuous for months.  
 
 
4.2 Diagnosis and preoperative screening 
 
Once CRC is suspected, the patient is usually directed to colonoscopy. In case a malignant 
tumor is found, biopsies from the tumor tissue can be taken directly for further 
immunohistochemical and genetic analyses. Another widely-used method is detecting 
hemoglobin in the stools, but the sensitivity of this test is only 33–75%, and it does not allow 
taking biopsies or removing lesions at the time of detection (Simon, 2016).  
Magnetic resonance imaging (MRI) is primarily used in preoperative imaging of rectal cancer. 
It allows preoperative radiological T-staging (Figure 1, Table 2) and estimating the status 
between the tumor, mesorectal fascia, and other surrounding organs (Giusti et al., 2012). 
MRI is recommended for preoperative staging of all CRC patients (Dewhurst et al., 2012, 
Rollvén et al., 2013), but in clinical practice, computed tomography (CT) is more commonly 
used. In addition, endorectal ultrasound examination may provide useful information in the 
staging of superficial tumors (Taylor et al., 2008, Brown et al., 2004). 
In recent years, other diagnostic imaging methods of primary CRC have also been widely 
investigated. These include CT colonography and positron emission tomography (PET)/CT 
colonography (Kijima et al., 2014). The merits of CT colonography are that it allows the 
evaluation of not only the colon, but also extracolonic findings, such as lymph node, liver, 
and lung metastases (Mainenti et al., 2006) with a low radiation dose (Yee et al., 2013). In 
addition, using 3D technique enables visualization of the vascular anatomy before 
laparoscopic surgery (Hirai et al., 2013).  
PET is an imaging method based on visualizing enhanced metabolic processes, such as those 
within tumors, in the body. PET/CT colonography may be used for evaluation of recurrent 
CRC, but at present, it is recommended only for selected patients because of its 
expensiveness and limited resolution (Kijima et al., 2014).  
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Systemic disease is usually excluded with contrast-enhanced whole-body CT. If liver 
metastases are detected, the patient is further directed to high-resolution MRI imaging of 
the liver, which is especially beneficial in case of liver steatosis or contradictory CT results 
(Van Cutsem et al., 2016). PET with 18F-fluorodeoxyglucose integrated with CT (18F-FDG 












4.3 Classification and staging 
 
Approximately 70% of CRCs are diagnosed in the colon and 30% in the rectum (Gaertner et 
al., 2015). Of the colon cancers, 22–44% have been reported to be right-sided and 56–78% 
left-sided (Boeckx et al., 2017, Lee et al., 2019a).  
Approximately 20% of CRC patients have metastatic disease at the time of diagnosis (van der 
Geest et al., 2015, Yu and Cheung, 2018, Riihimäki et al., 2016), and at least 30% develop 
metastases later (Kanas et al., 2012). Up to 75% of the metastases are found in the liver 
(Sorbye et al., 2007). In recent European studies, 14.5–17.7% of the patients diagnosed with 
CRC have had synchronous liver metastases, and 7.1–12.8% have developed metachronous 
metastases after the operation on the primary tumor (Manfredi et al., 2006, Hackl et al., 
2014, Engstrand et al., 2018). The majority of the liver metastases are diagnosed within 
three years after the diagnosis of the primary tumor, and they are found more often among 
males than among females and in lower age categories than higher (Hackl et al., 2014).  
 
The staging of colorectal cancer at the time of diagnosis is the cornerstone of all treatment. 
The tumor/node/metastasis (TNM) classification and staging are presented in Table 2. Prior 
to the 21st century, disease stage was usually determined according to the Dukes’ 
classification system (Akkoca et al., 2014, Sarma, 1986, Turnbull et al., 1967), which has since 
been largely replaced by the TNM classification. In this thesis, Dukes’ classification was used 
in Study I, and TNM classifications 5–7 were used in Studies II–IV. There was some variation 
in the staging systems over the years according to the updates that were regularly made, but 




Table 2. TNM 8 classification and staging of colorectal cancer. The previously used Dukes’ 
classification included. 
TNM classification Definition 
T X 
0 
The primary tumor cannot be defined 
No evidence of primary tumor 
1 Tumor grows into the submucosa 
2 Tumor grows into the muscularis propria 
3 Tumor grows into the subserosa or into pericolic or perirectal 
tissues 
4 a Tumor grows through the wall of the bowel into the visceral 
peritoneum 
b Tumor grows into or is attached to other tissues or organs 
N X 
0 
Lymph nodes cannot be evaluated 
No lymph node metastases 
1 a 1 lymph node metastasis 
b 2–3 lymph nodes metastases 
c Tumor deposits without lymph node metastases 
2 a 4–6 positive lymph nodes 
b ≥7 positive lymph nodes 
M 0 No distant metastases 
1 a Cancer has spread to 1 distant organ 
b Cancer has spread to >1 distant organs 




I T1-2N0M0 A 
II A T3N0M0 B 
B T4aN0M0 
C T4bN0M0 










IV A Any T any N M1a D 
B Any T any N M1b 
C Any T any N M1c 
Adapted from the TNM Classification of Malignant Tumours (Brierley et al., 2017) and the modified 





5.1 Surgical treatment of primary colorectal tumors 
 
Surgery for primary colorectal tumors is indicated in patients with local tumors, and in 
metastatic disease, if all the metastases are considered operable. The location of the primary 
tumor defines the surgical technique. Surgery can be either mini-invasive (laparoscopic or 
robotic) or open. In the former, perioperative recovery is usually faster, need for analgesics 
briefer, and incisions smaller. The rates of intra- and postoperative complications and 
postoperative mortality are similar, and no differences in the oncological outcomes have 
been observed (Fleshman et al., 2019, Liu et al., 2018, Baik et al., 2011, Buunen et al., 2009).  
 
In colon cancer, the increasingly used surgical technique is complete mesocolic excision 
(CME). The procedure of choice depends on the location of the primary tumor, and the 
options are right hemicolectomy, extended right hemicolectomy or left hemicolectomy (Kim 
et al., 2016).  
In rectal cancer, the standard technique is total mesorectal excision (TME). The most 
important surgical prognostic factors are the circumferential resection margin (CRM), which 
should be created along the mesorectal fascia (MRF), and removal of all mesorectal lymph 
nodes. Sphincter-sparing surgery is favored, if possible (Glynne-Jones et al., 2017). 
 
Before surgery, most rectal cancer patients are directed to preoperative radiotherapy with 
or without sensitizing chemotherapy to reduce the risk of local recurrence. Only in the most 
favorable cases (cT1–2, cT3a/b, cN0–1), surgery alone is an option. In more locally advanced 
cases, either short-course radiotherapy or long-course chemoradiotherapy is recommended. 
The standard options are the following: a 25 Gy total dose at 5 Gy/fraction during 5–7 days, 
followed by surgery either within 5 days or after 5–9 weeks; or a 45–50 Gy total dose in 25–
28 fractions, optionally followed by a 5.4 Gy boost in 3 fractions, if the CRM is threatened 
(van der Valk et al., 2020, Hyöty et al., 2019, Glynne-Jones et al., 2017). In inoperable cases, 
neoadjuvant therapy with (chemo)radiation and chemotherapy is also an option.  
 
At the Helsinki University Hospital, the treatment of colon and rectal cancer patients is 
decided on at multidisciplinary team (MDT) meetings including gastrointestinal surgeons, 





5.2 Surgical and ablative treatments of liver metastases 
 
5.2.1 Liver resection 
The possibilities of curative-intent surgery should always be assessed, when liver metastases 
are diagnosed. The treatment of liver metastases has evolved significantly in the last couple 
of decades, and the resection rates have increased correspondingly (Adam and Kitano, 2019, 
Hackl et al., 2014). At the Helsinki University Hospital, the number of resections for 
colorectal metastases has over doubled: altogether 133 resections were performed between 
the years 2000 and 2005; 214 in 2006–2010; 250 in 2011–2014; and 339 in 2015–2018 
(Professor Helena Isoniemi, personal communication). 
Earlier, liver metastases were considered resectable, if their number was 1–3, maximum 
diameter 5 cm, or potential resection margin at least 1 cm (Isoniemi and Osterlund, 2011). 
Nowadays, defining resectability has become more complicated, and the decisions on the 
liver resections are made at MDT meetings. The goal is to achieve complete negative 
resection margins while preserving at least 30% of the estimated total liver volume as a 
future liver remnant (FLR) and sparing at least two Couinaud’s segments (Figure 2). In 
addition, portal and arterial inflow, venous outflow, and biliary drainage have to be 
maintained (Van Cutsem et al., 2016).  
 
 
Figure 2. Couinaud’s segments of the liver. 
 
Original image from: Curley SA, Glazer ES. Hepatic resection techniques. In: UpToDate, Post TW (Ed), 
UpToDate, Waltham, MA (http://www.uptodate.com). Accessed on October 15, 2020.  
Copyright © 2020 UpToDate, Inc. Reproduced and modified with permission. 
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Advances in surgical techniques have enabled resecting multiple bilobar liver metastases 
that cannot be removed at a single operation. This can be accomplished by a technique 
called two-stage hepatectomy (TSH), which was first introduced by Adam et al. in 2000 
(Adam et al., 2000) and comprises two separate interventions. At the first stage, the 
metastases in the left liver lobe are removed, and the contralateral portal vein branches are 
occluded either by surgical ligation or radiological embolization. This leads to hypertrophy of 
the FLR, and after 4–6 weeks, the remaining liver metastases in the right lobe can be 
resected at the second stage (Kabir et al., 2020). In addition, a variant of this technique 
called Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) has 
been developed. In ALPPS, an additional transection of the liver parenchyma along the 
falciform ligament is performed at the first stage, resulting in rapid hypertrophy of the FLR 
already within 1–2 weeks (Schnitzbauer et al., 2012, Kabir et al., 2020). These techniques can 
be applied to selected patients.  
Before liver resection, all patients undergo CT and high-resolution MRI imaging, as described 
in section 4.2. 18F-FDG PET/CT may be used for excluding extrahepatic spreading, and the 
liver metastases are further visualized with ultrasound during the operation (Van Cutsem et 
al., 2016).  
 
At the Helsinki University Hospital, the follow-up after liver resection continues at the 
department of oncology, at first with an interval of three months. Laboratory tests and CT 
imaging are performed before every appointment. In addition, all patients have a three 
months’ postoperative control at the clinic of liver surgery with laboratory tests, imaging, 
and clinical examination. High-resonance MRI imaging of the liver is performed in addition to 
CT, if necessary. The regular controls are continued for 5 years with gradually lengthening 
intervals, if no recurrence develops. In case a recurrence is detected, the oncological 
treatment is continued, and re-resection of the metastases may be considered with the 
same criteria as for primary liver resection (Hyöty et al., 2019).  
 
 
5.2.2 Ablative treatments of liver metastases 
For patients with oligometastatic disease – that is, 5 or more metastatic lesions at up to 3 
different sites – curative-intent surgery combined with local ablative therapy may be an 
option. In addition, localized interventions can be considered in order to achieve long-term 
disease control. The treatment of choice depends on the site and volume of the metastases, 
and the options include radiofrequency ablation (RFA), microwave ablation, brachytherapy 
electroporation, stereotactic body radiotherapy (SBRT), selective internal radiation therapy 
(SIRT), and transarterial chemoembolisation (TACE), among others (Peltola et al., 2019, Van 
Cutsem et al., 2016). Currently, the possibilities of using these local interventions are 




5.3 Oncological treatment 
 
At present, an increasing number of chemotherapy regimens are available, and their use is 
adjusted individually according to the molecular and pathological features of the cancer, 
clinical characteristics of the patient, and the results of the surgical procedures, not 
forgetting the preferences of the patients themselves. However, the basis of all present 
oncological treatment in CRC lies on a few chemotherapy agents (cytostatics) that continue 
to be widely used. 
 
 
5.3.1 Chemotherapy agents 
Fluoropyrimidines are a group of antimetabolite drugs that were found to have anticancer 
effects already in the 1950’s (Heidelberger et al., 1957). Of these, 5-fluorouracil (5-FU), a 
synthetic analogue of the naturally occurring pyrimidine derivative uracil, has been used in 
the treatment of colon cancer for decades. In vivo, 5-FU is converted to several metabolites 
that incorporate into DNA and RNA, and to fluorodeoxyuridine monophosphate, which is an 
inhibitor of the enzyme called thymidylate synthase. All of these inhibit DNA synthesis and 
thus, tumor growth (Diasio and Harris, 1989). 5-FU is administered parenterally 
(intravenously, i.v.), and more than 80% of it is metabolized in the liver. Leucovorin (LV), a 
compound similar to folinic acid, is usually administered simultaneously to enhance the 
anticancer effects of the drug.  
There are over 10 different forms of 5-FU, of which three orally (p.o.) administered prodrugs 
are commonly used in the treatment of CRC. Capecitabine is a fluoropyrimidine carbamate 
that passes unaltered through the intestine and is then metabolized via three steps to its 
active form, 5-FU, in the liver. Tegafur, on the other hand, is converted to 5-hydroxytegafur, 
which then breaks down spontaneously to form 5-FU (Thorn et al., 2011). The third option, 
S-1, is a drug consisting of three pharmacological agents: tegafur, gimeracil, and oteracil 
potassium (Kwakman et al., 2019).  
Treatment with 5-FU can cause several side effects including diarrhea, nausea, mouth sores, 
and fatigue. It may also cause severe, dose-limiting or even lethal toxicity, especially in 
patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This defect is caused by a 
mutation in the DPYD gene, and its prevalence in the general population is unknown. It is 
estimated that 2–8% of the patients may be vulnerable to toxic reactions to 5-FU (Boisdron-
Celle et al., 2017), and routine testing for DPD deficiency before initiating fluoropyrimidine-
based chemotherapy is currently generally recommended (Argiles et al., 2020).  
 
Oxaliplatin is a platinum-based antineoplastic agent that belongs to the same family as 
cisplatin and carboplatin. It inhibits DNA synthesis selectively through binding to the guanine 
and cytosine moieties, which leads to cross-linking of DNA. Oxaliplatin is administered i.v., 
typically in combination with 5-FU/LV i.v. (FOLFOX) or capecitabine p.o. (CAPOX). In stage IV 
CRC, other drugs can also be added to the combination.  
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Oxaliplatin typically causes acute cold-induced neurotoxicity and chronic neuropathy, which 
affect basically all patients (Griffith et al., 2017). The chronic neuropathy develops 
cumulatively according to the administered doses, and it may not be regressive in all cases. 
Oxaliplatin can also cause other side effects, such as an anaphylactic reaction. 
 
Irinotecan hydrochloride is a half-synthetic analogue of camptothecin, an extract from a 
Chinese tree Camptotheca acuminate (Fujita et al., 2015). It inhibits specifically the type I 
DNA topoisomerase, resulting in single-strand DNA breaks and irreversible inhibition of DNA 
synthesis. These events arrest the cell cycle in the S-G2 phase and lead to apoptosis. The use 
of irinotecan should be monitored carefully, as it may cause severe diarrhea. Other typical 
side effects include nausea, loss of appetite, chest pain, mucositis, and neutropenia. 
Irinotecan is administered i.v., usually in combination with 5-FU/LV i.v. (FOLFIRI) or 
capecitabine p.o. (CAPIRI), but it can be combined with other drugs too. 
 
 
5.3.2 Targeted therapies 
Targeted therapies have been used in metastatic (stage IV) colorectal cancer for more than 
15 years, and the commonly used drugs include vascular endothelial growth factor (VEGF) 
and epidermal growth factor receptor (EGFR) inhibitors. These can be administered in 
combination with other chemotherapy drugs or as monotherapy (Van Cutsem et al., 2016).  
 
VEGF, also known as VEGF-A, is a major angiogenic factor that promotes sprouting in tumors 
and contributes to tumor growth and metastasis. In addition, the other isoforms of VEGF 
(VEGF-B, -C, and -D) as well as placental growth factor (PlGF) also induce angiogenesis 
(Tammela et al., 2008, Tammela et al., 2005). EGFR, on the other hand, is a transmembrane 
tyrosine kinase protein that is involved in the RAS-RAF-MAPK signaling pathway, which 
mediates signals from outside a cell to the nucleus and regulates the growth, differentiation, 
proliferation, migration, and apoptosis of the cell. Activation of EGFRs also inhibits 
autophagy (Sigismund et al., 2018).  
 
VEGF inhibitor bevacizumab is a recombinant humanized monoclonal antibody that binds to 
circulating VEGF-A, and thus, inhibits the activation of VEGF receptors (Ferrara et al., 2005). 
This leads to decreased sprouting and tumor growth. Bevacizumab is recommended for the 
treatment of metastatic CRC in combination with chemotherapy drugs, especially in RAS- or 
BRAF-mutated colon cancer and in right-sided disease. Other anti-angiogenic agents, such as 
regorafenib, aflibercept, and ramucirumab, have also been adopted to later-line clinical use 
in CRC (Tampellini et al., 2016, Van Cutsem et al., 2016). 
EGFR inhibitors cetuximab and panitumumab are monoclonal antibodies that specifically 
bind to the EGFR, which results in the inhibition of the RAS-RAF-MAPK pathway (section 
7.3.1) and, consequently, decrease in tumor proliferation and growth. EGFR inhibitors are 
recommended for the first-line treatment of metastatic CRC in left-sided RAS-wild-type 
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cancer in combination with chemotherapy drugs, and for later-line treatment either alone or 
combined (Van Cutsem et al., 2016) (Table 3).  
 
Immunotherapies are an emerging treatment modality in solid cancers, but in CRC, they 
have not been of great benefit by far. However, the programmed cell death 1 (PD1) blocking 
antibodies pembrolizumab and nivolumab have shown promising efficacy in some patients 
with metastatic MSI-H/dMMR disease (Andre et al., 2020, Le et al., 2020, Ganesh et al., 
2019) (sections 6.1 and 7.3.2).  
 
 
5.3.3 Adjuvant chemotherapy in primary colorectal cancer 
In colon cancer, the adjuvant treatment begins 3–6(–8) weeks after the operation on the 
primary tumor, and its duration is 3–6 months, depending on the stage of the disease, risk 
factors, and possible adverse effect profile (Argiles et al., 2020). In local stage I colon cancer, 
no adjuvant treatment is needed. In stage II, adjuvant treatment is considered for high-risk 
patients, and the options are fluoropyrimidines alone or in combination with oxaliplatin 
(CAPOX/FOLFOX). In stage III, adjuvant treatment is usually indicated, and the standard 
option is fluoropyrimidines with or without oxaliplatin. 
 
The treatment of rectal cancer differs from that of colon cancer. Most rectal cancer patients 
receive radiotherapy with or without chemosenzitation therapy before the operation on the 
primary tumor, as described previously (section 5.1). After the operation, 5-FU alone or 
combined with oxaliplatin may be considered as adjuvant therapy (Benson et al., 2018b, 
Glynne-Jones et al., 2017).  
 
 
5.3.4 Chemotherapy in patients with resectable liver metastases 
The oncological treatment options in stage IV CRC have improved substantially in the last 
decades, and patient survival accordingly. The role of chemotherapy administered before 
(neoadjuvant) and/or after (adjuvant) liver resection has been evaluated in several studies 
(Wang et al., 2015, Nordlinger et al., 2013, Ciliberto et al., 2012, Mitry et al., 2008). 
Currently, perioperative – that is, both neoadjuvant and adjuvant – chemotherapy is 
recommended for most patients undergoing resection, but in selected cases with a good 
prognosis, the operation may be performed without preceding neoadjuvant therapy (Hyöty 
et al., 2019, Benson et al., 2018a, Benson et al., 2018b, Van Cutsem et al., 2016, Nordlinger 
et al., 2013). However, adjuvant therapy is usually indicated, as it has been shown to extend 
the disease-free survival time (Wang et al., 2015, Nordlinger et al., 2013, Ciliberto et al., 
2012). The type of treatment is discussed and decided on at MDT meetings, in which a 
gastrointestinal surgeon, a liver and/or thoracic surgeon, an oncologist, a radiologist, and a 
pathologist are present.  
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Liver resection may be performed directly in patients who have isolated liver metastases 
that are technically resectable, no extrahepatic disease, no other risk factors for poor 
prognosis, and who are at a sufficiently good physical condition. Only around 20% of the 
liver metastases are initially subject to curative-intent resection (Nordlinger et al., 2007, 
Khatri et al., 2005). In those cases, the recommended adjuvant chemotherapy is oxaliplatin-
based (CAPOX/FOLFOX) and its duration 6 months (Table 3). If oxaliplatin is contraindicated, 
fluoropyrimidine alone is an option (Hyöty et al., 2019, Van Cutsem et al., 2016).  
 
If the liver metastases are primarily easily resectable, but the patient has other risk factors 
for adverse prognosis or other operable metastases in addition to those in the liver, 
perioperative chemotherapy is indicated. The choice of neoadjuvant treatment depends on 
individual factors, but usually the recommended option is oxaliplatin-based (FOLFOX) (Van 
Cutsem et al., 2016) (Table 3). The duration of neoadjuvant chemotherapy is generally three 
months.  
Adjuvant chemotherapy is started within 3–6 weeks after liver resection, and its duration 
should be at least three months, so that the combined duration of both neoadjuvant and 
adjuvant treatment is six months (Wang et al., 2015, Nordlinger et al., 2013, Ciliberto et al., 
2012). The chosen treatment is preferably oxaliplatin-based as in neoadjuvant 
chemotherapy, unless contraindicating side effects have emerged.  
 
 
5.3.5 Conversion chemotherapy 
Nowadays even 30–61% of the initially non-resectable liver metastases can be rendered to 
resectable due to preoperative conversion chemotherapy (Stintzing et al., 2016, 
Gruenberger et al., 2015) (Figure 3). This therapy option may be considered for patients who 
have initially non-resectable liver metastases or metastases that are difficult to resect 
(borderline-resectable). The aim is to achieve maximal response rate and tumor shrinkage by 
using the most efficient chemotherapy regimens. If the patient’s physical condition allows, 
targeted drugs are combined to the previously described baseline chemotherapy regimens 
as presented in Table 3. The treatment response is evaluated at MDT meetings at an interval 
of two months, and liver resection is performed as soon as a sufficient treatment response is 
attained, usually after 2–4 months.  
After liver resection, adjuvant treatment is continued aiming at a total treatment duration of 
six months. However, targeted drugs are left out of the adjuvant treatment, as detriment 
has been observed in stage I–III disease (Van Cutsem et al., 2016, Hyöty et al., 2019).  
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Figure 3. Results of conversion chemotherapy in a 60-year-old patient with primarily non-
resectable liver metastases of a maximum diameter of 12.6 cm (A). After 3 months of 
chemotherapy with 5-FU/LV, oxaliplatin, and bevacizumab, the metastases had become 
operable (B). Couinaud’s segments 5–8 and part of 4b were resected (C). In the final 
pathological analysis, the maximum diameter of the metastases was only 6.8 cm (D). 
 
Images 3 A, B and D courtesy of Professor Helena Isoniemi, Helsinki University Hospital, Helsinki, 
Finland. Image 3 C modified from Curley SA, Glazer ES. Hepatic resection techniques. In: UpToDate, 
Post TW (Ed), UpToDate, Waltham, MA (http://www.uptodate.com). Copyright © 2020 UpToDate, 




5.3.6 Chemotherapy in non-operable metastatic disease 
The oncological treatment of metastatic, non-curable CRC aims at cytoreduction or control 
of disease progression. Important factors determining the prognosis include the molecular 
characteristics of the disease and the clinical presentation of the metastases. The choice of 
treatment is discussed with the patient, and their expectations, comorbidities, and the 
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The primary choice for first-line treatment is made following the same principles as in 
conversion chemotherapy, if cytoreduction is the goal (Table 3). When aiming at disease 
control, the treatment is less intensive. The factors considered include the sidedness of the 
primary tumor, the mutational status, and the patient’s medical condition and expectations. 
After a period of 4–6 months of induction therapy, either a treatment pause or maintenance 
therapy is commenced. In case of disease progression, the same systemic therapy is re-
introduced or the regimen is changed to a second-line option. It is quite common that a 
patient undergoes 3–4 lines of treatment before the period of best supportive care (Van 








6.1 Prognostic factors 
 
Several cancer- and patient-related, molecular, and genetic factors define the prognosis of 
CRC. Cancer-related risk factors for recurrence and poor prognosis include primary pT4 or 
pN2 stage, poor differentiation of the tumor(s), vascular and perineural invasion, obstruction 
or perforation of the bowel, as well as lymph node metastases after preoperative 
radio(chemo)therapy and insufficient resection margin in rectal cancer (Argiles et al., 2020). 
Patient-related risk factors include high age, physical frailty, comorbities, and liver 
insufficiency.  
Molecular and genetic factors contribute to the characteristics of the malignant tumors. 
BRAF mutated tumors and either stable or low degree of microsatellite instability (MSS or 
MSI-L, section 7.3.2) signify worse prognosis, even though the prognosis seems to be 
somewhat better in BRAF mutated disease with a high degree of microsatellite instability 
(MSI-H) or mismatch repair deficiency (dMMR) (Ogino et al., 2012). In addition, KRAS 
mutations have been associated with an increased risk of recurrent disease (Hutchins et al., 
2011), but the results have been controversial.  
 
 
6.2 Overall survival in colorectal cancer 
 
The prognosis of CRC is substantially affected by the location of the primary tumor, the 
mutational status, and the primary TNM status, among other clinical factors. In non-
metastatic CRC, all diagnosed patients combined, 5-year overall survival (OS) has been 60–
75% in recent European studies, and 10-year OS around 30% (Engstrand et al., 2018, Hackl et 
al., 2014).  
 
When the location of the primary tumor is taken into account, the prognosis in stage II colon 
cancer is quite similar to that of stage I disease. In stage III, 5-year cancer-specific survival 
rates of 57% in left-sided cancer and almost 55% in right-sided cancer have been reported 
(Lee et al., 2019a). In stage IV disease, however, significant differences have been found in 
several studies. In RAS/BRAF wild-type patients, all oncological treatments combined, 
median OS has been around 33 months in left-sided cancer and 22 months in right-sided 
cancer (Boeckx et al., 2017).  
In rectal cancer, 5-year OS is more than 90% in stage I disease, and declines to less than 10% 





6.3 Survival in colorectal cancer with liver metastases 
 
Survival rates after liver resection are constantly improving. In the last decade, 5-year 
survival rates of up to 53% (Stelzner et al., 2019, Engstrand et al., 2018, Hackl et al., 2014, 
Kanas et al., 2012) and 10-year cancer-specific survival of 23% (Rees et al., 2008) have been 
reported. For patients who undergo two-stage hepatectomy, 5-year OS has been 32–70% 
(Kabir et al., 2020). The patients who receive conversion chemotherapy before liver 
resection have slightly shorter postoperative survival than those who do not need it, but 
their prognosis is, in any case, significantly better than in case resection was not carried out 
(Van Cutsem et al., 2016, Adam et al., 2004).  
Mortality in liver surgery is low, being currently close to 1% (Isoniemi and Osterlund, 2011). 
Despite of the improved treatments, up to 70% of the patients experience recurrence after 
curative-intent liver resection (House et al., 2010), usually within three years. However, re-
resections are possible in selected cases with promising results.  
 
The location of the primary tumor affects the prognosis also after liver resection, as the 
patients with right-sided primary tumors tend to have worse survival than those with left-
sided tumors (Gasser et al., 2019) (sections 3.3 and 7.3.1). Median OS rates of 4.5 years in 
patients with right-sided primary tumors and 6.3 years in those with left-sided ones after 
liver resection have been reported (Elizabeth McCracken et al., 2019).  
 
The prognosis of the patients not suitable for liver resection is poor: with palliative 
chemotherapy, one-year survival rate of up to 58.1% has been reported (Engstrand et al., 
2018), but 5-year survival rates have been only 2.2–4.0% (Engstrand et al., 2018, Hackl et al., 
2014, Manfredi et al., 2006). With best supportive care, one-year survival is around 8.2% and 





7. PROGNOSTIC AND PREDICTIVE BIOMARKERS 
 
Prognostic biomarkers help evaluate the patient’s prognosis, for example, the risk of 
recurrence. They do not, however, predict the response to a specific treatment. Predictive 
biomarkers, on the other hand, aim to evaluate the patient’s likelihood of benefit from 
specific clinical interventions, such as an operation or chemotherapy (Mehta et al., 2010). In 
this thesis, the investigated biomarkers can be considered both prognostic and predictive, as 
their concentrations or expressions may be prognostic of recurrence or death and predictive 
of the benefit of liver resection. 
The serum/plasma biomarkers were determined principally in serum samples, and only the 
concentrations of tumor-associated trypsin inhibitor (TATI) and human chorionic 
gonadotropin β (hCGβ) were measured in plasma samples. Serum is a specimen obtained 
from full blood that has coagulated and from which fibrin clots, blood cells, and other 
coagulation factors are separated by centrifugation. Plasma is obtained, if an anticoagulant 
is added to the specimen before the removal of blood cells, and no time for coagulation is 
required. The sensitivity of the biomarker determinations may be better in serum because of 
higher metabolite concentrations, but on the other hand, plasma has demonstrated a better 
reproducibility, possibly due to the less complicated collecting procedure. In principle, serum 
and plasma are, however, considered to be equal for biomarker determinations (Yu et al., 
2011, Lima-Oliveira et al., 2018). 
 
 
7.1 Biomarkers in this thesis 
 
7.1.1 Carcinoembryonic antigen (CEA) 
CEA, first identified by Gold and Freedman in 1965 (Gold and Freedman, 1965), is the most 
commonly used biomarker in the detection and management of CRC. It is a glycoprotein 
functioning as an intracellular adhesion molecule, currently categorized as a member of the 
immunoglobulin superfamily. The production of CEA is normally minimal after birth, but 
elevated levels in serum have been detected in several malignancies, such as colorectal 
(Carpelan-Holmström et al., 1995), gastric (Shimada et al., 2014), pancreatic (Zhang et al., 
2018b), breast (Uehara et al., 2008), and lung cancer (Molina et al., 2008). In addition, 
smoking (Alexander et al., 1976) and non-neoplastic conditions (Hao et al., 2019), such as 
alcoholic liver disease (Bell et al., 1979), diabetes (Chung et al., 2019), chronic renal failure 
(Filella et al., 1990), and inflammatory bowel diseases (Gardner et al., 1978), can cause CEA 
levels to increase.  
 
In local CRC, elevated serum levels have been associated with recurrent disease after the 
operation on the primary tumor (Ramphal et al., 2019, Konishi et al., 2018, Baqar et al., 
2019, Carpelan-Holmstrom et al., 2004), and also in CRC with liver metastases, elevated CEA 
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levels before or after liver resection have indicated recurrence (Bredt and Rachid, 2014, 
Okazaki et al., 2017).  
 
At present, CEA is the only biomarker recommended for monitoring CRC. It should be 
measured for all the newly diagnosed CRC patients as well as in the follow-up after curative-
intent surgery (Sturgeon et al., 2008, Duffy et al., 2007, Locker et al., 2006, Duffy et al., 
2003). However, it has been reported in several studies that approximately 30–40% of CRCs 
do not produce elevated levels of CEA despite of metastatic disease (Saito et al., 2018, 
Thomsen et al., 2018). Thus, there is an obvious need for more reliable biomarkers. 
 
 
7.1.2 Carbohydrate antigen 19-9 (CA19-9) 
CA19-9 (sialyl Lewis A) is a tetrasaccharide characterized as sialylated lacto-N-fucopentaose 
II (Magnani et al., 1981, Magnani et al., 1982). It is normally produced by pancreatic and 
biliary ductal cells as well as by gastric, colonic, endometrial, and salivary epithelia. It was 
originally discovered in 1979 and, subsequently, identified as a tumor marker in 1981 
(Koprowski et al., 1981). Soon afterwards, CA19-9 in serum was found to be elevated in 
gastrointestinal malignancies, such as pancreatic cancer (Del Villano et al., 1983, Jalanko et 
al., 1984), cholangiocarcinoma (Jalanko et al., 1984), colorectal cancer (Koprowski et al., 
1981, Sears et al., 1982, Kuusela et al., 1984), and gastric cancer (Yang et al., 2014, Liang et 
al., 2016). In pancreatic adenocarcinoma, serum CA19-9 has recently been found to be 
useful for estimating the response to neoadjuvant chemotherapy and survival (Al Abbas et 
al., 2020). In CRC, CA19-9 is currently not recommended in the routine follow-up, as its 
sensitivity has been found to be inferior to that of CEA in detecting recurrences (Okamura et 
al., 2017). However, it is considered an emerging prognostic biomarker (Duffy et al., 2014, 
Yakabe et al., 2010). In addition, it has been suggested that CA19-9 might be a target for 
therapeutic antibodies in the treatment of gastrointestinal malignancies (Weitzenfeld et al., 
2019, Sawada et al., 2011, Ragupathi et al., 2009).  
 
 
7.1.3 Human chorionic gonadotropin β (hCGβ) 
Human chorionic gonadotropin (hCG) belongs to a family of glycoprotein hormones together 
with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating 
hormone (TSH).  These consist of two distinct subunits, α and β. The α subunits are identical, 
while the β subunits are specific and account for the biological characteristics of the 
individual hormones.  
HCG is normally produced by syncytiotrophoblastic cells of the placenta during pregnancy, 
and it is a specific marker for malignant tumors of trophoblastic origin. HCG has also been 
suggested to act as an angiogenic factor in tumor development (Zygmunt et al., 2002). The 
free β subunit (hCGβ) can be detected in tissue, serum, and urine. Elevated serum 
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concentrations of hCGβ have been observed in several non-trophoblastic malignancies 
including ovarian (Marcillac et al., 1992, Vartiainen et al., 2001), gastric (Louhimo et al., 
2004), colorectal (Lundin et al., 2001, Louhimo et al., 2002), biliary (Alfthan et al., 1992), 
pancreatic (Alfthan et al., 1992, Syrigos et al., 1998), and hepatocellular cancer (HCC) 
(Lyytinen et al., 2013), and they have associated with adverse prognosis. 
 
In CRC, the prognostic significance of elevated hCGβ concentrations in serum has been 
controversial. It has been considered inferior to CEA in detecting recurrent disease 
(Carpelan-Holmstrom et al., 2004), but on the other hand, it has been found to predict 
adverse outcome in women (Birgisson et al., 2012).  
 
 
7.1.4 Tumor-associated trypsin inhibitor (TATI) 
TATI is a 6-kDA peptide that was originally identified in the urine of a patient with ovarian 
cancer (Stenman et al., 1982, Huhtala et al., 1982). It was later found to be identical to 
pancreatic secretory trypsin-inhibitor (PSTI / serine peptidase inhibitor Kazal type 1 
[SPINK1]), which had been previously isolated from the bovine pancreas (Greene and 
Giordano, 1969). TATI is normally produced by pancreas (Eddeland and Ohlsson, 1978, 
Hedström et al., 2001) as well as by several other tissues (Lasson et al., 1986, Halila et al., 
1985, Jönsson et al., 1996), and it can be detected in tissue samples, serum, and urine. TATI 
is a protease inhibitor that can inhibit the degradation of extracellular matrix by tumor cells 
(Koivunen et al., 1991). On the other hand, it has been shown to be involved in angiogenesis 
and to promote tumor growth (Gouyer et al., 2008). TATI is structurally similar to epidermal 
growth factor (EGF) (Scheving, 1983), and it has been shown to stimulate EGF receptors, and 
thus, to increase tumor invasiveness (Ozaki et al., 2009). In addition, it acts as an acute phase 
reactant (Ogawa et al., 1985).  
 
Increased serum levels of TATI have been observed in several malignancies, and they have 
been shown to have prognostic value in ovarian (Venesmaa et al., 1998, Paju et al., 2001), 
renal (Paju et al., 2004), bladder (Kelloniemi et al., 2003), gastric (Kasurinen et al., 2020), and 
colorectal cancer (Gaber et al., 2010, Gaber et al., 2011) as well as in HCC (Lyytinen et al., 
2013). Studies concerning the prognostic value of serum TATI in CRC have been few, but in 
the studies by Gaber et al., TATI was found to be an independent prognostic biomarker and 
possibly even of stronger prognostic value than CEA. The prognostic role of TATI in CRC, 





7.1.5 YKL-40, interleukin-6 (IL-6), and C-reactive protein (CRP) 
Systemic inflammation has been associated with impaired prognosis in several malignancies 
(Hanahan and Weinberg, 2011, Nasr et al., 2018). YKL-40 (also called chitinase-3-like protein-
1 [CHI3L1]), IL-6, and CRP are established biomarkers of systemic inflammation, and their 
potential role as prognostic biomarkers in cancer has raised growing interest during the last 
decades.  
 
YKL-40 is a glycoprotein that was identified in a human osteoblastoma cell line in 1992 
(Johansen et al., 1992). It belongs to the family of chitinase-like proteins that includes also 
YKL-39 and stabilin-1 interacting chitinase-like protein (SI-CLP). These proteins are secreted 
by cancer cells and various other cell types including macrophages, neutrophils, 
synoviocytes, and chondrocytes, among others (Kzhyshkowska et al., 2016). The function of 
YKL-40 is not completely known, but it promotes tumor invasion and metastasis via several 
mechanisms, mainly by contributing to angiogenesis independently and by inducing VEGF 
expression (Francescone et al., 2011). In addition, YKL-40 upregulates proinflammatory 
mediators (Libreros et al., 2012) and activates the TGFβ pathway (Qiu et al., 2018) as well as 
the Akt signaling pathway in colonic epithelial cells (Chen et al., 2011). It interacts with 
several receptors, such as IL-13Rα2 and the receptor for advanced glycation end products 
(RAGE) (Yeo et al., 2019).  
Soon after discovery, elevated serum levels of YKL-40 were found to associate with poor 
overall survival in patients with recurrent breast cancer (Johansen et al., 1995). Since then, 
elevated serum or plasma YKL-40 has also been shown to indicate poor prognosis in several 
other malignancies including colorectal (Cintin et al., 1999, Cintin et al., 2002, Fuksiewicz et 
al., 2018), ovarian (Høgdall et al., 2003, Dupont et al., 2004), hepatocellular (Zhu et al., 
2012), pancreatic (Palmquist et al., 2020), and lung cancer (Xu et al., 2014) as well as 
melanoma (Ismail et al., 2019).  
 
IL-6 is a proinflammatory cytokine, more specifically a 21–28 kDa 4-helix bundled 
glycoprotein (Rossi et al., 2015), which is secreted by macrophages and various cancer cells 
(Tanaka et al., 2016, Yeo et al., 2019). It was first shown to induce B lymphocytes to produce 
immunoglobulin and to stimulate hepatocytes (Hirano et al., 1986). IL-6 is involved in several 
biological processes including autoimmune diseases (Jones et al., 2018) and cancer (Yeo et 
al., 2019, Vainer et al., 2018). IL-6 stimulates the production of YKL-40 and CRP (Tanaka and 
Kishimoto, 2012, Nielsen et al., 2011, Nishikawa et al., 2008), and it has been shown to 
induce tumor growth and metastasis (Zhang et al., 2018a, Jayatilaka et al., 2017). In addition, 
IL-6 is involved in the formation of a pro-metastatic niche in the liver, and thus, liver 
metastasis (Lee et al., 2019b). In pancreatic cancer, elevated serum IL-6 alone and in 





CRP is the first identified acute-phase protein (Abernethy and Avery, 1941), and it was 
originally named for its capacity to precipitate the somatic C-polysaccharide of Streptococcus 
pneumoniae. CRP is produced by hepatocytes (Uete et al., 1971), even though other sites of 
synthesis have also been suggested. It has been widely used in the clinic for decades as a 
biomarker of systemic inflammation and tissue damage (Pepys and Baltz, 1983, Pepys and 
Hirschfield, 2003). At present, growing interest is focused on high-sensitivity CRP (hsCRP), 
which is more precise than standard CRP and can be measured at very low concentrations by 
high-sensitivity assays (Pearson et al., 2003).  
Recently, the interest in CRP as a possible cancer biomarker has grown. Elevated serum and 
plasma levels of CRP have been associated with impaired prognosis in several cancers, such 
as prostate (Liao et al., 2020, Stikbakke et al., 2020), cervical (Wang et al., 2020), lung 
(Pastorino et al., 2019), and colorectal cancer (Matsubara et al., 2020, Kim et al., 2018, 
Thomsen et al., 2016). In CRC with liver metastases, elevated CRP before liver resection has 
been found to be a strong predictor of impaired prognosis (Kostner et al., 2016).  
 
 
7.1.6 Matrix metalloproteinases 2, 8, and 9 (MMP-2, -8, and -9) 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are structurally 
related but genetically distinct. They are enzymes capable of degrading almost all proteins in 
the extracellular matrix (ECM). The first metalloproteinase, collagenase, was found in 1962 
(Gross and Lapiere, 1962), and since then, altogether 28 members in vertebrates have been 
identified. Of these, at least 23 are expressed in human tissues. MMPs can be divided into six 
categories according to substrate specificity, sequential similarity, and domain organization 
(Laronha and Caldeira, 2020, Wang and Khalil, 2018) (Table 4). They are secreted by various 
cells and tissues as inactive (latent) proMMPs, which contain a cysteine switch. When the 
switch is cleaved by other proteolytic enzymes, such as other MMPs, they become activated 
(Nagase et al., 2006, Cui et al., 2017).  
MMPs have several important functions in tissue remodeling, inflammation, and 
pathogenesis. By degrading ECM and non-matrix proteins, they facilitate malignant tumor 
growth and invasion. They can also regulate immune responses by processing different 
bioactive substances including growth factors, cytokines, chemokines, and serum proteins 
(Sorsa et al., 2006). The activity of MMPs increases significantly in inflammatory diseases and 
malignancies (Sorsa et al., 2004). 
The proteolytic activity of the MMPs is regulated via mRNA expression, activation of the 
proenzymes, and by endogenous proteins (Visse and Nagase, 2003, Cui et al., 2017). It has 
been demonstrated that trypsin-2, the major isoenzyme of human tumor-associated 
trypsinogens, can directly activate collagenolytic MMPs (Moilanen et al., 2003). TATI and 
tissue inhibitors of metalloproteinases (TIMPs), in turn, regulate and inhibit MMPs (Chirco et 




MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) are both type IV collagenases, and they are 
involved in cancer invasion and metastasis. MMP-2 is mainly produced by dermal fibroblasts, 
leukocytes, and platelets (Saito et al., 2001, Seizer and May, 2013). MMP-9 is produced by 
various cells including epithelial cells, fibroblasts, macrophages, granulocytes, and T-cells 
(Cui et al., 2017, Wang and Khalil, 2018).  
Increased tumor expression of both MMP-2 and MMP-9 has been associated with poor 
prognosis in recurrent glioblastoma (Zhou et al., 2019) and gastric cancer (Yao et al., 2017, 
Mrena et al., 2006, Zhang et al., 2003). MMP-2 expression has indicated impaired prognosis 
also in several other malignancies including colorectal (Deng et al., 2017), breast 
(Talvensaari-Mattila et al., 2003), esophageal (Ao et al., 2013), and endometrial cancer 
(Honkavuori-Toivola et al., 2013) as well as osteosarcoma (Zhang and Zhang, 2015). MMP-9 
expression in tumor tissue, on the other hand, has been associated with improved prognosis 
in extrahepatic bile duct cancer (Park et al., 2018) and HCC (Chen et al., 2012). In CRC, 
interestingly, positive expression has indicated both impaired prognosis (Chu et al., 2012) 
and improved prognosis (Koskensalo et al., 2012b).  
Contrary to the tissue expression of MMP-9, its serum or plasma concentrations have not 
had significant prognostic value despite of active investigation. By far, this has been noted in 
CRC (Liang and Chang, 2018), lung cancer (Gong et al., 2016), and HCC (Lempinen et al., 
2013). 
 
MMP-8 (collagenase-2, neutrophil collagenase) is produced mainly by neutrophils and 
macrophages (Wang and Khalil, 2018), but also by several other cell types (Van Lint and 
Libert, 2006). Besides degrading the ECM, MMP-8 has been found to impair migration of the 
tumor cells via transforming growth factor-β1 (TGF-β1) and vascular endothelial growth 
factor-C (VEGF-C) in oral squamous cell cancer (Åström et al., 2017). As the expressions of 
other MMPs, those of MMP-8 in tumor tissue and serum have been widely investigated in 
different malignancies. In CRC patients, the serum levels have been shown to be significantly 
increased compared to healthy subjects (Väyrynen et al., 2012).  
The results concerning the prognostic value of the tissue expression of MMP-8 in malignant 
tumors have been variable (Juurikka et al., 2019), and MMP-8 has primarily been reported to 
have tumor-suppressing qualities. In breast cancer models, MMP-8 has prevented invasion 
and metastasis (Agarwal et al., 2003, Montel et al., 2004), and the expression in breast 
cancer tumors has correlated with lower incidence of lymph node metastases (Gutiérrez-
Fernández et al., 2008). MMP-8 has also been shown to protect against the development of 
skin tumors in mice (Balbín et al., 2003), and its expression has associated with improved 
survival in squamous cell cancer of the mobile tongue (Korpi et al., 2008).  
On the contrary, elevated serum concentrations of MMP-8 have been associated with 
impaired prognosis in CRC (Sirniö et al., 2018, Böckelman et al., 2018, Väyrynen et al., 2012) 
and HCC (Lempinen et al., 2013). In gastric cancer, both elevated and low serum 
concentrations have indicated poor survival (Laitinen et al., 2018). Based on these findings, it 
seems possible that the tissue expression and serum concentrations of MMP-8 have distinct 
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prognostic value. Sirniö et al. found that there was no correlation between the density of 
tumor-infiltrating neutrophils and serum MMP-8 levels, suggesting that the neutrophils in 
circulation might be a source of serum MMP-8 (Sirniö et al., 2018). In addition, it is worth 
mentioning that Linkov et al. observed that MMP-8 levels in serum are unique to each 
person, indicating that knowing the individual baseline for every patient might help using 
MMP-8 as a prognostic biomarker (Linkov et al., 2009). 
 
 
Table 4. The human matrix metalloproteinase (MMP) family grouped according to substrate 
specificity, sequential similarity, and domain organization. 
Group MMPs included 
Collagenases 1, 8, 13 
Gelatinases 2, 9 
Stromelysins 3, 10, 11 
Matrilysins 7, 26 
Membrane-type MMPs (MT-MMPs) 14 (MT 1), 15 (MT 2), 16 (MT 3), 17 (MT 4), 24 
(MT 5), 25 (MT 6) 
Other MMPs 12, 19, 20, 21, 23, 27, 28 
Adapted from (Laronha and Caldeira, 2020, Wang and Khalil, 2018, Visse and Nagase, 2003). 
 
 
7.1.7 Myeloperoxidase (MPO) 
MPO is a heme-containing lysosomal enzyme that is found mainly in neutrophilic 
granulocytes and in smaller quantities also in monocytes and macrophages (Krawisz et al., 
1984). Inflammation induces its production by those cells. When activated, MPO uses H2O2 
to oxidize chloride ions and other halides, which leads to the formation of hypochlorous acid 
(HOCl), among others (Gomez-Mejiba et al., 2010, Klebanoff et al., 2013). HOCl can 
subsequently oxidize DNA in inflammatory cells and surrounding epithelial cells. During this 
process, DNA-centered free radicals are formed, which leads to the production of several 
oxidation products. DNA damage causes increased mutations and alters the function of 
enzymes and proteins that subsequently contribute to carcinogenesis (Ohshima et al., 2003). 
In addition, MPO can activate latent MMPs via the production of HOCl (Weiss et al., 1985, 
Saari et al., 1990).  
 
On the other hand, MPO is thought to be needed for the defensive immune responses to 
function optimally. MPO can oxidatively inactivate pathogenic microbes as well as tissue 
inhibitor of metalloproteinases-1 (TIMP-1) (Sorsa et al., 2006), and it is known that patients 
with genetic MPO deficiency can have increased number of infections of variant degree of 
severity (Parry et al., 1981).  
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In cancer, MPO is an emerging biomarker, but there are by far only a few studies on its 
prognostic value. High infiltration of MPO-expressing neutrophilic granulocytes in tumors 
has been associated with favorable prognosis in both colorectal and breast cancer (Droeser 
et al., 2013, Zeindler et al., 2019). In a study by Coelho et al., serum levels of MPO were 
found to be higher in breast cancer patients than in healthy volunteers, and they associated 
with lymphovascular invasion negativity (Coelho et al., 2014). Thus, it seems possible that 
MPO has a protective role in cancer, but its prognostic value remains to be established.  
 
 
7.1.8 Transketolase-like protein 1 (TKTL1) 
Tumor cells require energy for survival and proliferation. Unlike cells in healthy tissues, they 
are able to consume glucose and to convert it to lactate even in the presence of oxygen. This 
phenomenon is known as the Warburg effect, and it was originally observed by Otto 
Warburg already in 1924 (Warburg et al., 1924). Normally, degradation of glucose happens 
via two main pathways: the Embden-Meyerhof pathway, and the pentose phosphate 
pathway (PPP). The non-oxidative part of the PPP is catalyzed by transketolase (TKT) enzyme 
reactions, which enable oxygen-independent glucose degradation.  
Three human transketolase genes encoding corresponding enzymes have been identified: 
TKT, transketolase-like 1 (TKTL1), and transketolase-like 2 (TKTL2) (Coy et al., 2005, Langbein 
et al., 2006). Of the three enzymes, TKTL1 is suggested to account for the tumor-specific 
effects of transketolase enzyme reactions (Langbein et al., 2006), and its role in tumor cell 
metabolism and cancer progression has been under active investigation in recent years. 
 
By far, the expression of TKTL1 in tumor tissue has been associated with impaired survival in 
CRC (Ahopelto et al., 2016, Schwaab et al., 2011, Langbein et al., 2006), laryngeal squamous 
cell carcinoma (Völker et al., 2007), non-small cell lung cancer (Kayser et al., 2011), and 
gastric cancer (Ahopelto et al., 2020, Song et al., 2015). In addition, Diaz-Moralli et al. (Diaz-
Moralli et al., 2011) found that the expression of TKTL1 in primary colorectal tumors 
increased progressively in disease stages I to III, but in stage IV, there was a strong decrease, 
suggesting that the expression pattern changes along with metastasis formation.  
 
 
7.2 Other potential biomarkers in CRC 
 
Several biomarkers have raised interest as potential predictors of the outcome of CRC 
patients in the past years. Carbohydrate antigens CA12-5, CA19-5, CA242, CA50, and CA72-4 
have been reported to be inferior to CEA and CA19-9. In some cases, however, CA242 has 
shown superior prognostic value compared to CA19-9 in predicting 5-year relapse-free 




Some studies have evaluated the prognostic value of matrix metalloproteinases 7 (Vočka et 
al., 2019), 13, and 21 (Huang et al., 2011) as well as TIMP-1 (Böckelman et al., 2018, Vočka et 
al., 2019), and the results have been promising. Other biomarkers of interest include, for 
example, vascular endothelial growth factor (VEGF) (Mohamed et al., 2019) and 
inflammatory cells, mainly neutrophils, T-cells, and macrophages (Governa et al., 2017, 
Wikberg et al., 2017).  
 
 
7.3 Genetic alterations 
 
7.3.1 Mutations 
The most important genetic mutations observed in CRC are those in the RAS (KRAS, NRAS, 
and HRAS), BRAF, p53, and PIK3CA genes, and the most common of these are the KRAS and 
BRAF mutations. KRAS and BRAF are both proteins that belong to the RAS-RAF-MAPK 
signaling pathway, which mediates signals from outside a cell to the nucleus and, thus, 
regulates the growth, differentiation, proliferation, migration, and apoptosis of the cell. The 
KRAS gene encodes a guanosine triphosphatase (GTPase) protein called KRAS, and the BRAF 
gene a serine/threonine kinase, which is a protein belonging to the RAF family. KRAS can be 
activated by stimuli from the transmembrane EGF receptor, and the activation of KRAS, in 
turn, activates the BRAF kinase. Mutations in either the KRAS or BRAF gene cause a 
continuous activation of the corresponding protein, leading to uncontrolled dividing and 
growth of tumor cells via the signaling cascade (Santarpia et al., 2012).  
 
RAS mutations are present in 43–58% of CRCs, most typically in right-sided tumors 
(Serebriiskii et al., 2019, Rimbert et al., 2018, Loree et al., 2018), and they have been shown 
to predict non-responsiveness to EGFR inhibitor therapy (Di Fiore et al., 2007, Lièvre et al., 
2008). BRAF mutations occur in 10–22% of CRCs, also more often in right-sided disease. They 
are predictive of particularly poor prognosis and resistance to EGFR inhibitors unless the 
carcinoma shows microsatellite instability (Phipps et al., 2015).  
Other mutations that associate with impaired prognosis include TP53 mutations, which have 
been reported to be present in approximately 50% of CRCs, and PIK3CA mutations that occur 
in 10–30% of the cases (Therachiyil et al., 2020, Tejpar et al., 2010, Ogino et al., 2009). In 
addition, chromosome 18q loss of heterozygosity (18qLOH) (Sarli et al., 2004) has been 
associated with impaired overall survival. Other genes that are under active studying include 
PTEN, UGT1A1, CTNNB1, FGFR3, GNAS, HER2, and SMAD4. The prevalence of the mutations 
depends on the location of the primary tumor (Loree et al., 2018). 
 
The research on these genes and their prognostic as well as predictive significance 
continues. At the Helsinki University Hospital, the mutation status has been routinely tested 
in all patients with metastatic CRC since 2013.  
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7.3.2 Microsatellite instability (MSI) 
Microsatellites are repeated DNA sequences, as described in the previous section 3.1, and 
the MSI status in colorectal tumors is a defining factor of prognosis and response to 
treatment. In addition, it has importance as a screening tool for hereditary CRC.  
The MSI status is classified as follows: either 1) high degree of instability (MSI-H), or 2) low 
degree of instability (MSI-L) or microsatellite stable (MSS), together referred to as non-MSI-
H. In the latter, the tumor has no characteristics of MSI. In addition, the presence or absence 
of a functional MMR system, which indirectly demonstrates the MSI status, can be classified 
as 1) deficient MMR (dMMR), leading to a mutator phenotype, or 2) proficient MMR 
(pMMR), meaning that small errors during DNA replication are repaired normally. 
Approximately 15% of sporadic CRCs are defined as MSI-H/dMMR tumors (Lee and Chu, 
2018, Lech et al., 2016). 
 
MSI-H/dMMR status is predictive of a good prognosis, independently of the stage of CRC, 
and non-MSI-H of a poor outcome (De' Angelis et al., 2018). This is thought to be caused by a 
strong antitumoral response in the patient. As the mutations accumulate in the MSI-
H/dMMR tumors, the immune system is activated, and an increased cytolytic response in 
the patient is triggered, leading to elimination of the tumor cells (Drescher et al., 2009). MSI-
H/dMMR CRCs have been found to be insensitive to 5-FU (Argiles et al., 2020), which affects 
the choice of oncological treatment.  
 
At the Helsinki University Hospital, the MSI status has been tested in all patients with 
metastatic CRC since 2018.  
 
 
7.4 Emerging technologies 
 
MicroRNAs (miRNAs) are small, single-stranded, non-coding RNAs. MiRNA genes are prone 
to damage because of their chromosomal location. In CRC, miRNAs have been shown to be 
frequently deregulated, and this can lead to silencing tumor suppressor genes or activating 
oncogenes and, consequently, cancer progression (Lin and Gregory, 2015, Yiu and Yiu, 2016).  
MiRNAs can be detected in serum or plasma, various body fluids, and tissue samples, and 
they are considered potential markers for screening, prognosis, and response to treatment 
in CRC.  
 
Liquid biopsies constitute an emerging technology, which has great potential in the 
detection and management of CRC and is likely to be applied to clinical use shortly. Liquid 
biopsy testing means analyzing different biomarkers in any body fluid, for example, blood, 
urine, or cerebrospinal fluid. Through liquid biopsies, circulating tumor cells (CTCs), 
circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), RNA, miRNA, and several different 
proteins can be analyzed (Normanno et al., 2018).  
47 
 
AIMS OF THE STUDY 
 
 
The aim of this thesis was to evaluate the prognostic significance of selected biomarkers in 
colorectal cancer with resectable liver metastases. The study material consisted of patients 
undergoing curative-intent liver resection.  
 
The specific aims were to evaluate the associations of the following biomarkers with disease-
free/relapse-free survival and overall survival after liver resection: 
 
 
1. Pre- and postoperative CEA and CA19-9 in serum (I and II) 
 
2. Pre- and postoperative hCGβ and TATI in plasma (I) 
 
3. Pre- and postoperative YKL-40, IL-6, and CRP in serum combined with CEA and 
CA19-9 in serum (II) 
 
4. Tissue expressions of MMP-2, MMP-8, and MMP-9 in primary colorectal tumors and 
liver metastases as well as pre- and postoperative MMP-8, MMP-9, and MPO in 
serum (III) 
 







MATERIALS AND METHODS 
 
 
1. PATIENTS (I–IV) 
 
Altogether 462 patients with colorectal cancer metastasized to the liver underwent their first 
liver resection with a curative intent at the Helsinki University Hospital between the years 
1998 and 2013. The primary colorectal tumors were operated on at different hospitals in 
Finland between 1988 and 2013. Of all patients, 20 were excluded from these studies 
because of either extrahepatic metastases that could not be operated on or non-curative 
liver resection. 
These studies are based on the serum samples from all patients (I–III), the plasma samples 
from a subset of 168 patients (I), and the tissue samples from a subset of 111 patients (III 
and IV) who had both their primary colorectal tumors and liver metastases operated on at 
the Helsinki and Uusimaa Hospital District between 1988 and 2007. The designs of the four 
studies are shown in Table 5. 
 
Liver metastases were defined as synchronous, if they were diagnosed at the same time with 
the primary colorectal tumor or within six months after the operation on the primary tumor. 
Liver resection was considered major, if more than two Couinaud’s segments were removed.  
 
Clinical data were retrieved from patient records, and information about the dates of death 
was obtained from the Central Statistical Office of Finland (TK-53-1004-9). The studies were 
approved by the Ethics Committee at the Helsinki University Hospital (IRB99/07/01; 
HUS531/E6/01; HUS460/E6/05; HUS323/13/3/2008; HUS242/13/03/02/2011; Dnro HUS 
226/E6/06, extension TMK02 §66 17.4.2013). Collection and analysis of blood and tissue 
samples were approved by the National Supervisory Authority for Welfare and Health 
(Valvira) (STM Dno 4858/04/047/08; Valvira Dnro 10041/06.01.03.01/2012). 
 
 
2. SERUM AND PLASMA SAMPLES (I–III) 
 
The serum and plasma samples (I–III) were drawn in conjunction with the liver resection, 
before and approximately 3 months after the operation. The median time between 
preoperative sampling and the liver resection was 17 days (IQR 9–29 days), and the median 
time between the resection and postoperative sampling 94 days (IQR 89–98 days). The 
samples of CEA, CA19-9, and CRP were analyzed when taken. The samples of hCGβ, TATI, 
YKL-40, IL-6, MMP-8, MMP-9, and MPO were centrifuged within ½ to 2 hours, and they were 
stored at -80 Celsius until analyzed.  
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The serum concentrations of CEA and CA19-9 were determined with either an 
immunoenzymatic assay, Bayer Immuno 1 (CEA: 1998–10/2005; and CA19-9: 1998–1/2006), 
or an immunochemiluminometric assay, Abbott Architect (CEA: 10/2005–2013; and CA19-9: 
1/2006–2013), and those of CRP with an immunoturbidimetric method. The samples were 
analyzed at HUSLAB laboratories, Helsinki University Hospital, and the results were retrieved 
from clinical records. The serum levels of CEA were expressed as µg/l, those of CA19-9 as 
kU/l, and those of CRP as mg/l. 
 
The plasma concentrations of hCGβ were quantified by an immunofluorometric assay (IFMA) 
based on monoclonal antibodies (Stenman et al., 2004), and those of TATI by a time-resolved 
IFMA (Janeiro et al., 2012). The detection limits were 0.5 pmol/l for hCGβ and 0.15 µg/l for 
TATI. 
 
The serum concentrations of YKL-40 and IL-6 were determined using commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (YKL-40: MicroVue YKL-40 ELISA [Catalog 
#8020], Quidel Corporation, San Diego, CA, USA; and IL-6: Quantikine HS600B, R&D Systems, 
Abingdon, OX, UK). The detection limit for YKL-40 was 20 ng/ml, and the intra- and 
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interassay CVs <5% and <6%, respectively (Bojesen et al., 2011). The detection limit for IL-6 
was 0.01 pg/ml, and the intra- and interassay CVs ≤8 and ≤11%, respectively (Knudsen et al., 
2008).  
 
The serum concentrations of MMP-8 were measured by a time-resolved IFMA (Mauramo et 
al., 2018). The monoclonal MMP-8-specific antibodies 8708 and 8706 (Oy Medix Biochemica 
Ab, Espoo, Finland) were used as a catching and a tracer antibody, respectively. The tracer 
antibody was labeled using europium chelate (Hemmilä et al., 1984). The assay buffer 
contained 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 5 mM CaCl2, 50 μM ZnCl2, 0.5% BSA, 0.05% 
sodium azide, and 20 mg/l DTPA. Samples were first diluted in assay buffer and incubated for 
1 hour, and then they were incubated for 1 hour with the tracer antibody. Enhancement 
solution was added, and after 5 minutes, fluorescence was measured using a 1234 Delfia 
Research Fluorometer (Wallac, Turku, Finland). The detection limit for MMP-8 was 0.08 
ng/ml and the CV 7.3%.  
The serum concentrations of MMP-9 and MPO were determined using commercially 
available ELISA kits according to the manufacturers’ instructions (MMP-9: Amersham 
BioSciences UK Ltd., Buckinghamshire, UK; and MPO: Immundiagnostik AG, Bensheim, 
Germany). The detection limit for MMP-9 was 0.6 ng/ml (Mäkitalo et al., 2012) and that for 
MPO 1.6 ng/ml (Pradhan-Palikhe et al., 2010).  
 
 
3. TUMOR TISSUE SPECIMENS (III and IV) 
 
The tissue samples of primary colorectal tumors and liver metastases were fixed in formalin 
and embedded into paraffin immediately after the operations. The paraffin-embedded 
specimens and the hematoxylin-eosin stained slides made from each block were obtained 
from the Department of Pathology of the Helsinki University Hospital. One block of primary 
tumor tissue and one of liver metastasis tissue were chosen for each patient. In case of 
several tumor samples, the blocks with the largest amount of viable (non-necrotic) tumor 
tissue were chosen. Representative tumor areas and spots of healthy tissue were marked on 
the corresponding slides (RP) and verified by an experienced pathologist (JH). Six punches of 
1,000 µm in diameter were taken from the tumor areas and two from the healthy tissue 
areas of each block. The punches were taken with a semiautomatic tissue microarray (TMA) 
Grand Master 3D instrument (Histech Ltd, Budapest, Hungary) and mounted on TMA 
paraffin blocks. Two series of blocks were subsequently constructed, both containing three 
samples of the patients’ colorectal tumor tissue, three samples of liver metastasis tissue, and 





4. IMMUNOHISTOCHEMISTRY (III and IV) 
 
TMA blocks were cut into 4-µm sections for immunohistochemistry and dried on the slides 
for 12–24 hours in 37 Celsius. The sections were then deparaffinized in xylene and 
rehydrated through a graded series of ethanol and distilled water. For antigen retrieval, Tris-
EDTA (pH 9) (MMP-2 and MMP-8) or Tris–HCl buffer (pH 8.5) (MMP-9 and TKTL1) was used, 
and the samples were heated in the PreTreatment module (Agilent Dako, Lab Vision Corp., 
Fremont, CA, USA) for 20 minutes at 98°C. 
 
Staining process was performed with the Lab Vision Autostainer 480 (LabVision Corp., 
Fremont, CA, USA) using Dako Real EnVision (ENV). First, the samples were incubated for 5 
minutes to inactivate endogenous peroxidases. Second, the slides were incubated with the 
chosen primary antibodies (Table 6) at room temperature using the Dako REAL Antibody 
Diluent S2022 (Dako). Third, the slides were incubated with the secondary antibody (Dako 
Real ENV rabbit/mouse HRP antibody) for 30 minutes, and then visualized with Dako Real 
ENV Dab chromogen kept on glass for 10 minutes. Between each step of the staining 
procedure, the slides were washed with PBS containing 0.04% Tween 20. The slides were 
counterstained with Dako Mayer’s Hematoxylin S3309, dehydrated through a graded series 
of water, ethanol, and xylene (aqua–70% ethanol–96% ethanol–absolute alcohol–xylene), 
and finally mounted using Pertex® Histolab mounting medium.  
Melanoma and tongue cancer specimens were used as positive controls for MMP-2, MMP-8, 
and MMP-9, and gastric and colon cancer as those for TKTL1.  
 
 
Table 6. Antibodies used in the immunohistochemical stainings. 
Biomarker Antibody Company Dilution 
(incubation) 
Staining Study 










MMP-8 In-house (Sorsa et 

















TKTL1 Mouse monoclonal 
anti-human TKTL1 
(RIDA PentoCheck 










5. SCORING (III and IV) 
 
The immunohistochemical staining intensities of colorectal tumor tissue and liver metastasis 
tissue were scored independently by two researchers (study III: RP and JH; study IV: KA and 
JH) without knowledge of the clinical data. In case of different scoring results, the samples 
were re-evaluated until consensus was reached. The highest score was chosen to represent 
each sample. Tissue spots without tumor cells or with too few cells for adequate judging 
were excluded.  
The maximum number of tumor tissue spots per slide was 56, and the area of each spot was 
0,79 mm2. As there were altogether 6 spots of both colorectal tumor and liver metastasis 
tissue per patient, the analyzed area was approximately 4.7 mm2 of colorectal tumor and 4.7 
mm2 of liver metastasis tissue per patient. 
 
The scoring of MMP-2 (III) was based on the intensity of cytoplasmic staining in tumor cells 
as follows: 0: no positivity in any cancer cells; 1: mild staining in all or some cancer cells; 2: 
moderate staining in most cancer cells; and 3: strong staining in all cancer cells (Figure 4, 
page 59).  
 
The expression of MMP-8 (III) was graded depending on the amount of stained inflammatory 
cells in immediate proximity to the tumor cells as follows: 0: no staining or only one stained 
granulocyte; 1: some stained granulocytes; 2: several stained granulocytes; and 3: 
abundantly of stained granulocytes (Figure 4).  
 
The expression of MMP-9 (III) was scored based on the intensity of granular cytoplasmic 
staining in tumor cells as follows: 0: no staining; 1: mild granulary staining in some cancer 
cells; 2: moderate granulary staining in all or some cancer cells; and 3: strong granulary 
staining in all cancer cells (Figure 4). In liver tissue, no staining or only mild granulary staining 
was seen as well as some stained inflammatory cells. 
 
The scoring of TKTL1 expression (IV) was based on the intensity of cytoplasmic staining in 
tumor cells as follows: 0: no staining; 1: mild staining; 2: moderate staining; and 3: strong 
staining (Figure 4). In normal liver tissue, TKTL1 expression was visible in epithelial cells, in 





6. STATISTICAL ANALYSES (I–IV) 
 
The distributions of the biomarkers in different subgroups of patients were assessed using 
the Mann-Whitney U test and the Kruskal-Wallis H test. Correlations between the 
biomarkers or the biomarkers and clinicopathological variables were estimated with the 
Spearman’s correlation test (I–IV), Wilcoxon signed-rank test (II), and the Fisher’s exact test 
(III). Cut point analyses for CEA, CA19-9, hCGβ, TATI, YKL-40, IL-6, CRP, MMP-8, MMP-9, and 
MPO (I–III) were performed using ROC curves and calculating the area under the curve.  
 
Overall survival (OS) was calculated from the date of the liver resection to the date of death 
from any cause, and disease-free/relapse-free survival (DFS [I, III, and IV] / RFS [II]) was 
defined as the time from the liver resection to the first recurrence of CRC or death. Patients 
alive without recurrence were censored at the end of follow-up. Univariate and multivariate 
survival analyses were performed using Cox proportional hazards model. Survival curves 
were created according to the Kaplan-Meier method and compared with the log-rank test.  
The variables included in the multivariate Cox regression analyses (I and II) were the 
following: study I: serum or plasma concentrations of the investigated biomarkers (CEA, 
CA19-9, hCGβ, and TATI), type of liver metastases (synchronous/metachronous), and 
adjuvant chemotherapy (yes/no); and study II: serum concentrations of the biomarkers (YKL-
40, IL-6, CRP, CEA and CA19-9), age, gender, location of the primary tumor, type of liver 
metastases (synchronous/metachronous), type of liver resection (minor/major), the number 
and size of the liver metastases, and the resection margins (R0/1/2). In studies III and IV, 
multivariate analyses were not performed, because it was estimated that their statistical 
reliability would be controversial due to the quite small patient cohort.  
 
Statistical analyses were carried out and survival curves were created using SPSS Statistics 
versions 22 (I) and 25 (III and IV) (SPSS Inc., Chicago, IL, USA) or the statistical software R 
version 3.3.3 (R Core Team, Vienna, Austria) (II). In studies I, III, and IV, the biomarkers were 
included in the survival analyses using specified cut-off values. In studies II and IV, they were 
also included as log2-transformed continuous variables. A p-value of less than 0.05 was 






1. PATIENT CHARACTERISTICS (I–IV) 
 
The clinicopathological characteristics of the patients included in the four studies are 
presented in Table 7. The median age of all patients at the time of the operation on the 
primary tumor was 63.3 years (min. 31.3–max. 82.1) and at the time of the liver resection 
64.8 years (min. 33.0–max. 84.0). Altogether 58.8% (260/442) of the patients were male, and 
49.1% (217/442) of them were over 65 years old at the time of the liver resection. The 
primary tumor was located in the rectum in 41.6% (184/442), in the left colon or 
rectosigmoid junction in 39.4% (174/442), and in the right or transversal colon in 19.0% 
(84/442) of the cases. The median time between the operation on the primary tumor and 
the liver resection was 11.4 months (interquartile range [IQR] 5.9–25.4).  
Within the follow-up until January 11th, 2019, disease-free survival for all patients was 41.4% 
(183/442) at three years and 34.4% (152/442) at five years after liver resection. The 5-year 
overall survival rate was 56.8% (251/442). The median time to recurrence after liver 
resection was 9.8 months (IQR 3.5–17.7). 
 
 
2. CONCENTRATIONS AND EXPRESSIONS OF THE BIOMARKERS (I–IV) 
 
2.1 Biomarkers in serum and plasma (I–III) 
 
The median concentrations and the numbers of elevated biomarkers in studies I–III are 
presented in Table 8. In the statistical analyses, the same cut-off values were used for both 
pre- and postoperative biomarker concentrations, except for those of MMP-8 (study III).  
 
 
2.1.1 CEA and CA19-9 (I and II) 
In study I (N=168), the cut-off value for CEA was 5.0 µg/l and that for CA19-9 26 kU/l 
according to the reference limits that are routinely used in Finland. In study II (N=441), the 
cut-off values were calculated using ROC curve analyses in relation to 3-year RFS and 3-year 





Table 7. Characteristics of the patients included in the four studies. 
Characteristic n (%) or median (min.–max.) 
Study I Study II Studies III and IV 
N 168 441 111 
Gender 
     Male 










Age at the liver resection 
     Median (years) 











     Rectum 
     Left colon or rectosigmoid junction 
     Right or transversal colon 
 
67 (39.9) 










Primary TNM staging 
     Dukes’ A–B1 
     Dukes’ C–D1 
     Missing data 
     T1–2 
     T3–4 
     Missing data 
     N0 
     N1 
     N2 



































     Synchronous2 
     Metachronous 
     Number, median (max.) 















2.5 cm (9.0) 
Resection margins3 
     R0 
     R1 
     R2 
















Follow-up time, living patients (years) 
5-year disease-free survival 
5-year overall survival 













Recurrence or death within follow-up 
     Yes 










1 Dukes’ classification used only in Study I. TNM classification presented according to availability. 
2 Synchronous: diagnosed within 6 months after the operation on the primary tumor. 




Of all patients combined, 49.7% (219/441, missing 1) had a normal CEA level (≤5.0 µg/l) 
preoperatively. Of these CEA-negative patients, 31 (14.2%) had a CA19-9 level of >26 kU/l 
and 17 (7.8%) that of >37 kU/l. On the other hand, altogether 71.0% (311/438, missing 4) of 
the patients had a normal CA19-9 level (≤26 kU/l) preoperatively, and of those patients, 
39.9% (124/311) had elevated CEA. In total, 22.0% (96/437, missing 5) of the patients had 
elevated CEA (>5.0 µg/l) and a CA19-9 level of >26 kU/l preoperatively, and 19.0% (83/437) 
elevated CEA and a CA19-9 level of >37 kU/l. 
 
After liver resection, 83.2% (367/441, missing 1) of the patients had a normal CEA level (≤5.0 
µg/l), and of those, 36 (9.8%) had a CA19-9 level of >26 kU/l and 19 (5.2%) that of >37 kU/l. 
Altogether 85.6% (374/437, missing 5) of the patients had a CA19-9 level of ≤26 kU/l 
postoperatively, and of those, 12.6% (47/374) had elevated CEA. Only 6.2% (27/437, missing 
5) of the patients had postoperatively elevated CEA and CA19-9 >26 kU/l, and 5.5% (24/437) 
elevated CEA and CA19-9 >37 kU/l. 
 
 
2.1.2 HCGβ and TATI (I) 
The cut-off value for hCGβ was based on the 75th percentiles and that for TATI on the 
medians of both pre- and postoperative plasma concentrations, as the ROC curve analyses 
did not provide statistically significant cut points. The cut-off value for hCGβ was 1.0 pmol/l, 
and that for TATI 13 µg/l. 
 
 
2.1.3 YKL-40, IL-6, and CRP (II) 
The cut-off values for YKL-40, IL-6, and CRP were chosen based on the cut points with a 
sensitivity closest to 80% in the ROC curve analyses in relation to 3-year RFS and 3-year OS. 
An age-corrected 95th percentile in healthy individuals was chosen for YKL-40, and it was 
calculated as suggested by Bojesen et al. (Bojesen et al., 2011). The YKL-40 percentiles were 
derived as follows: percentile=100/(1+(YKL-40^-3)*(1.062^age)*5000).  
The cut-off value for IL-6 was 4.95 pg/ml, and that for CRP 5 mg/l.  
 
 
2.1.4 MMP-8, MMP-9, and MPO (III) 
For MMP-8, the tertiles of the preoperative values were used as cut points, as the ROC curve 
analyses lacked statistically significant results. The cut-off values were the following: 
preoperative MMP-8: 29.6 and 76.2 ng/ml; and postoperative MMP-8: 20.8 and 56.1 ng/ml.  
The cut-off levels for MMP-9 and MPO were chosen based on the ROC curve analyses in 




Table 8. Studies I–III: Concentrations of the biomarkers measured in serum/plasma before 
liver resection and three months after the operation. 






     Median (IQR) 
     >5.0 µg/l, n (%) 
CEA (N) 
     Median (IQR) 

















     Median (IQR) 
     >26 kU/l, n (%) 
CA19-9 (N) 
     Median (IQR) 













I hCGβ (N) 
     Median (IQR) 







I TATI (N) 
     Median (IQR) 







II YKL-40 (N) 
     Median (IQR) 







II IL-6 (N) 
     Median (IQR) 







II CRP (N) 
     Median (IQR) 







III MMP-8 (N) 
     Median (IQR) 
Preoperative: 
     29.7–76.2 ng/ml, n (%) 
     >76.2 ng/ml, n (%) 
Postoperative: 
     20.9–56.1 ng/ml, n (%) 

















III MMP-9 (N) 
     Median (IQR) 







III MPO (N) 
     Median (IQR) 







* >age-corrected 95th percentile in healthy individuals (Bojesen et al., 2011). 
IQR: interquartile range. 
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2.2 Biomarkers in tissue specimens (III and IV) 
 
The expressions of all the investigated biomarkers in tissue specimens of the primary 
colorectal tumors and the liver metastases are presented in Table 9. 
 
 
2.2.1 MMP-2, MMP-8, and MMP-9 (III) 
Staining of MMP-2 was visible in the cytoplasm and cell membranes of the tumor cells. In 
the statistical analyses, the negative and mildly positive samples (score 0–1) were grouped 
as “low”, and moderately and strongly stained samples as “high” expression (Figure 4). 
MMP-8 expression was seen in the granulocytes in close proximity to the tumor cells. 
Samples with zero or only a few stained granulocytes (score 0–1) were grouped as “low”, 
and samples with several or abundantly of stained cells (score 2–3) as “high” expression 
(Figure 4). 
Granulary staining of MMP-9 was seen in the cytoplasm of the tumor cells. The samples with 
no staining or only mild granulary staining in some tumor cells (score 0–1) were grouped as 
“low”, and those with moderate or strong granulary staining in several or all tumor cells 
(score 2–3) as “high” expression (Figure 4).  
 
 
Table 9. Studies III and IV: Expressions of the biomarkers in tissue samples of the primary 
colorectal tumors and the liver metastases. 
Study Tissue biomarkers’ 
expressions 
n (%) 
Colorectal tumors Liver metastases 
III MMP-2 (N) 
     0 
     1 
     2 











III MMP-8 (N) 
     0 
     1 
     2 











III MMP-9 (N) 
     0 
     1 
     2 











IV TKTL1 (N) 
     0 
     1 
     2 













2.2.2 TKTL1 (IV) 
Staining of TKTL1 was visible in the cytoplasm of the tumor cells. For the statistical analyses, 
the samples with negative, mild or moderate staining (score 0–2) were grouped as “low”, 




Figure 4. Studies III and IV: Immunohistochemical stainings of MMP-2, MMP-8, MMP-9, and 
TKTL1 grouped according to the expression level. Magnification x200. 
 
MMP-2, -8, and -9: low: score 0–1, high: score 2–3; TKTL1: low: score 0–2, high: score 3. 





3. CORRELATIONS (I–IV) 
 
3.1 The biomarkers’ serum and plasma concentrations (I–III) 
 
In study I, preoperative CEA correlated with preoperative CA19-9 (rho 0.40, p<0.001). 
Postoperative CEA correlated with postoperative CA19-9 (rho 0.18, p=0.019) and 
postoperative TATI (rho 0.16, p=0.033). Postoperative CA19-9 correlated with postoperative 
hCGβ (rho 0.21, p=0.008) in addition to CEA. Postoperative hCGβ correlated with pre- and 
postoperative TATI (rho 0.19, p=0.015; and rho 0.18, p=0.019, respectively).  
 
In study II, preoperative CEA correlated with preoperative CA19-9 (rho=0.41, p<0.001), 
preoperative YKL-40 (rho=0.11, p=0.027), and preoperative CRP (rho=0.22, p<0.001). 
Postoperative CEA correlated with postoperative CA19-9 (rho=0.22, p<0.001) and 
postoperative YKL-40 (rho=0.15, p=0.002). 
Pre- and postoperative CA19-9 correlated with CEA as mentioned above. Postoperative 
CA19-9 also correlated with postoperative IL-6 (rho=0.13, p=0.008) and CRP (rho 0.13, 
p=0.007).  
Pre- and postoperative YKL-40 correlated with CEA as mentioned above. In addition, 
preoperative YKL-40 correlated with preoperative IL-6 (rho=0.39, p<0.001) and preoperative 
CRP (rho 0.10, p<0.001), and postoperative YKL-40 with postoperative IL-6 (rho=0.28, 
p<0.001) and postoperative CRP (rho 0.18, p<0.001). 
IL-6 and CRP correlated with the other biomarkers as mentioned above. In addition, 
preoperative IL-6 correlated with preoperative CRP (rho=0.33, p<0.001), and postoperative 
IL-6 with postoperative CRP (rho 0.55, p<0.001).  
 
In study III, the serum values of MMP-8, MMP-9, and MPO all correlated with each other 
pre- and postoperatively (rho 0.20–0.70, p<0.001–0.001). 
 
 
3.2 The biomarkers’ expression in tissue specimens (III and IV) 
 
In study III, MMP-2 expression in the primary colorectal tumors correlated with that of 
MMP-8 in the primary tumors (rho -0.30, p=0.007), but not with the expression of MMP-9. 
No statistically significant correlations were found concerning MMP-2 expression in the liver 
metastases.  
MMP-8 expression in the primary tumors correlated only with that of MMP-2, as mentioned 
above. No correlations were found concerning the tissue expression of MMP-9 in the 
primary tumors or liver metastases.  
In study IV, TKTL1 expression in the primary colorectal tumors did not correlate with the 
expression in the liver metastases.  
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3.3 MMP-2, MMP-8, and MMP-9 expression in tissue specimens and MMP-8, 
MMP-9, and MPO in serum (III) 
 
The expression of MMP-2 in the primary colorectal tumors or the liver metastases did not 
correlate with the serum concentrations of MMP-8, MMP-9 or MPO, and neither did that of 
MMP-8 in the primary colorectal tumors. Instead, MMP-8 expression in the liver metastases 
correlated with both pre- and postoperative MMP-8 concentrations in serum (rho 0.33, 
p=0.002; and rho 0.24, p=0.027, respectively) as well as with preoperative MPO in serum 
(rho 0.22, p=0.044). MMP-9 expression in the primary colorectal tumors correlated with 
postoperative MMP-8 in serum (rho -0.43, p=0.002), when only patients with synchronous 
liver metastases were included. No correlations were found concerning the expression of 
MMP-9 in the liver metastases and the serum concentrations. 
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4. SURVIVAL ANALYSES (I–IV) 
 
4.1 Serum and plasma concentrations and survival (I–III) 
 
The results of the univariate Cox regression analyses according to specified cut-off levels in 
relation to DFS/RFS and OS are shown in Tables 10 and 11. 
 
4.1.1 CEA and CA19-9 and survival (I and II) 
In study I, Kaplan-Meier analyses showed that preoperatively elevated concentrations of CEA 
(>5.0 µg/l) associated with poor OS within three years after liver resection (p=0.010), but not 
within the whole follow-up time. There was no association with DFS. Postoperatively 
elevated CEA associated with shorter DFS and OS (both: p<0.001), and this finding remained 
significant in the multivariate analysis (3-year DFS: HR 3.78, p<0.001; OS: HR 3.68, p<0.001). 
Of the patients that experienced recurrence after liver resection, 78% (90/115) had a normal 
CEA level (≤5.0 µg/l) postoperatively, and these patients were found to develop recurrence 
later than those with elevated CEA postoperatively. Altogether 93% (107/115) of all 
recurrences were detected within 3 years after resection.  
Preoperatively elevated CA19-9 (>26 kU/l) associated with shorter OS (p=0.006), but not 
with DFS. Postoperatively elevated values associated with both shorter DFS and OS (p=0.011 
and p=0.002, respectively).  
Only 14.9% (11/74) of the patients with normal CEA had elevated CA19-9 preoperatively and 
9.9% (14/141) postoperatively. In those patients, CA19-9 was not prognostic.  
The postoperative concentrations of CEA in relation to 5-year DFS and 10-year OS, and the 
pre- and postoperative concentrations of CA19-9 in relation to 10-year OS are shown in 
Figures 5 and 6 with corresponding p-values.  
 
In study II, Cox regression method was used for the survival analyses, and the biomarkers 
were included in the analyses as log2-transformed continuous variables (Tables 12 and 13). 
Preoperative concentrations of CEA associated with poor OS (HR 1.07), but not with RFS. 
Postoperative concentrations associated with poor RFS (HR 1.24) and OS (HR 1.33), and the 
postoperative values remained significant in multivariate analysis (RFS: HR 1.17; OS: HR 
1.24).  
Concentrations of CA19-9 associated with both poor RFS and OS preoperatively (RFS: HR 
1.08; OS: HR 1.12) as well as postoperatively (RFS: HR 1.12; OS: HR 1.22). Pre- and 
postoperative CA19-9 remained significant also in the multivariate analyses in relation to RFS 
(HR 1.12 and HR 1.09, respectively) and OS (HR 1.13 and HR 1.17, respectively).  
CA19-9 was elevated (>37 kU/l) in 7.8% (17/219) of the patients with normal CEA (≤5.0 µg/l) 
before liver resection, and in 5.2% (19/366) of those with normal CEA postoperatively. In 
those cases, CA19-9 did not provide additional prognostic information regarding RFS and OS.  
63 
 
Figure 5. Study I: Postoperative serum concentrations of CEA in relation to A) 5-year  







4.1.2 HCGβ and TATI and survival (I) 
In the analyses according to the Kaplan-Meier method, preoperatively elevated hCGβ (>1.0 
pmol/l) did not associate with DFS or OS, and postoperatively an association was found only 
with poor OS within three years after liver resection (p=0.017).  
Instead, preoperatively elevated TATI (>13 µg/l) associated with shorter DFS within three 
years after liver resection (p=0.017) and also within the whole follow-up time nearly 
significantly (p=0.051), but not with shorter OS. Postoperatively measured TATI did not 
associate with DFS or OS.  
These findings were not significant in the multivariate analyses. 
 
For this thesis, the prognostic significance of hCGβ and TATI was further examined in 
specified subgroups of patients. These were created according to gender (male/female), age 
(under/over 65 years at the time of the liver resection), location of the primary tumor 
(rectum/colon), and the type of liver metastases (synchronous/metachronous). It was found 
that postoperatively elevated hCGβ (>1.0 pmol/l) indicated shorter OS among males 
(p=0.032), but not among females, and shorter DFS and OS in patients with primary rectal 
tumors (DFS: p=0.038; OS: p=0.003). In addition, preoperatively elevated TATI (>13 µg/l) 
associated with worse DFS among patients with synchronous liver metastases (p=0.029), but 
not among those with metachronous ones. Otherwise, no statistically significant associations 




Figure 6. Study I: Serum concentrations of CA19-9 A) preoperatively, and B) postoperatively            







Table 10. Studies I–III: Results of the univariate Cox regression analyses of the serum/plasma 
biomarkers in relation to disease-free/relapse-free survival. Reference values are those 
below the (lower) cut-off limit. Table contains previously unpublished data (R.P. 2020). 
Study Biomarker Cut-off value(s) n HR (95% CI) p-value 

























I hCGβ >1.0 pmol/l 41/168 0.95 (0.63–1.44) 0.802 
I TATI >13 µg/l 80/168 1.41 (1.00–2.00) 0.053 
II YKL-40 >95th percentile1 57/413 1.49 (1.10–2.03) 0.011 
II IL-6 >4.95 pg/ml 142/413 1.25 (0.98–1.58) 0.069 
II CRP >5 mg/l 86/429 1.16 (0.88–1.52) 0.289 








III MMP-9 >77.7 ng/ml 56/108 0.76 (0.49–1.16) 0.200 
III MPO >218.6 ng/ml 48/108 0.45 (0.29–0.71) 0.001 

























I hCGβ >1.0 pmol/l 38/168 1.15 (0.76–1.73) 0.523 
I TATI >13 µg/l 78/168 1.10 (0.78–1.56) 0.581 
II YKL-40 >95th percentile1 78/413 1.44 (1.09–1.89) 0.010 
II IL-6 >4.95 pg/ml 214/413 1.28 (1.02–1.61) 0.031 
II CRP >5 mg/l 129/434 1.35 (1.06–1.71) 0.014 








III MMP-9 >77.7 ng/ml 54/110 1.05 (0.69–1.60) 0.829 
III MPO >218.6 ng/ml 43/110 0.80 (0.51–1.24) 0.318 
1 >age-corrected 95th percentile in healthy individuals. 
2 Cut-off values according to the tertiles of the preoperative serum concentrations. 




Table 11. Studies I–III: Results of the univariate Cox regression analyses of the serum/plasma 
biomarkers in relation to overall survival. Reference values are those below the (lower) cut-
off limit. Table contains previously unpublished data (R.P. 2020). 
Study Biomarker Cut-off value(s) n HR (95% CI) p-value 

























I hCGβ >1.0 pmol/l 41/168 1.18 (0.77–1.80) 0.444 
I TATI >13 µg/l 80/168 1.21 (0.84–1.75) 0.302 
II YKL-40 >95th percentile1 57/413 1.77 (1.28–2.43) <0.001 
II IL-6 >4.95 pg/ml 142/413 1.30 (1.00–1.67) 0.048 
II CRP >5 mg/l 86/429 1.16 (0.87–1.56) 0.316 








III MMP-9 >77.7 ng/ml 56/108 0.89 (0.56–1.39) 0.600 
III MPO >218.6 ng/ml 48/108 0.56 (0.35–0.89) 0.015 

























I hCGβ >1.0 pmol/l 38/168 1.48 (0.97–2.25) 0.071 
I TATI >13 µg/l 78/168 1.11 (0.77–1.60) 0.586 
II YKL-40 >95th percentile1 78/413 1.72 (1.29–2.31) <0.001 
II IL-6 >4.95 pg/ml 214/413 1.31 (1.02–1.68) 0.032 
II CRP >5 mg/l 129/434 1.57 (1.22–2.02) <0.001 








III MMP-9 >77.7 ng/ml 54/110 1.30 (0.83–2.04) 0.250 
III MPO >218.6 ng/ml 43/110 0.92 (0.58–1.47) 0.731 
1 >age-corrected 95th percentile in healthy individuals. 
2 Cut-off values according to the tertiles of the preoperative serum concentrations. 





4.1.3 YKL-40, IL-6, CRP and survival (II) 
In the Cox regression analyses, the concentrations of YKL-40 associated with shorter RFS and 
OS, when measured before liver resection (RFS: HR 1.19; OS: HR 1.29) and three months 
after it (RFS: HR 1.21; OS: HR 1.26) (Table 12). In the multivariate analyses, however, only 
preoperative YKL-40 concentrations in relation to OS remained significant (HR 1.19) (Table 
13).  
IL-6 associated with shorter RFS (HR 1.15) and OS (HR 1.16) preoperatively and 
postoperatively (RFS: HR 1.11; OS: HR 1.13) (Table 12). These findings were not significant in 
the multivariate analyses. 
Elevated CRP (>5 mg/l) associated only with shorter OS postoperatively (HR 1.11), and only 
in the univariate analysis (Table 12).  
 
 
4.1.4 Combined prognostic value of serum YKL-40, IL-6, CRP, CEA, and CA19-9 (II) 
For further analyses, the serum concentrations of the inflammatory biomarkers YKL-40, IL-6, 
and CRP, and the cancer biomarkers CEA and CA19-9 were combined. Altogether 43.9% 
(175/399) of the patients had 2–5 biomarkers elevated preoperatively, and 41.4% (167/403) 
postoperatively.  
It was found that patients with 2–5 elevated biomarkers preoperatively had significantly 
shorter RFS (HR 1.37) and OS (HR 1.76) compared to those with 0–1 elevated biomarkers 
(Figure 7; Table 12), and this finding was significant also in the multivariate analyses (RFS: HR 
1.40; OS: HR 1.71) (Table 13). The same was true for postoperatively elevated values, as 2–5 
elevated biomarkers indicated worse RFS and OS in both the univariate (RFS: HR 1.54; OS: HR 
1.83) (Figure 8; Table 12) and the multivariate analyses (RFS: HR 1.57; OS: HR 1.84) (Table 
13).  
When compared to no elevated biomarker concentrations, having CEA and/or CA19-9 
elevated postoperatively associated with shorter RFS and OS (RFS: HR 1.87, 95% CI 1.36–
2.58, p<0.001; OS: HR 2.15, 95% CI 1.52–3.02, p<0.001), while having YKL-40, IL-6 and/or 






Figure 7. Study II: Kaplan-Meier curves of preoperative YKL-40, IL-6, CRP, CEA, and CA19-9 in 
serum showing the difference between 0–1 and 2–5 elevated biomarkers in relation to        







Table 12. Study II: Results of the univariate Cox regression analyses in relation to relapse-
free and overall survival. Biomarkers are presented as log2-transformed continuous 
variables. 
 n Relapse-free survival Overall survival 
HR (95% CI) p-value HR (95% CI) p-value 
Preoperative biomarkers 
CEA 440 1.01 (0.96–1.07) 0.583 1.07 (1.01–1.12) 0.019 
CA19-9 437 1.08 (1.03–1.14) <0.001 1.12 (1.06–1.18) <0.001 
YKL-40 413 1.19 (1.07–1.32) <0.001 1.29 (1.16–1.44) <0.001 
IL-6 413 1.15 (1.03–1.28) 0.010 1.16 (1.03–1.30) 0.011 
CRP 429 1.08 (0.96–1.21) 0.219 1.07 (0.95–1.21) 0.240 
0 elevated 111/399 Reference  Reference  
1 elevated 113/399 0.81 (0.58–1.12) 0.202 0.86 (0.60–1.24) 0.433 
2 elevated 101/399 1.13 (0.83–1.56) 0.438 1.63 (1.16–2.30) 0.005 
3 elevated 44/399 1.60 (1.08–2.36) 0.018 1.82 (1.19–2.79) 0.006 
4 elevated 29/399 1.57 (0.99–2.49) 0.055 1.78 (1.08–2.93) 0.023 
5 elevated 1/399 2.86 (0.40–20.7) 0.298 3.24 (0.45–23.5) 0.245 
0–1 elevated 224/399 Reference  Reference  
2–5 elevated 175/399 1.37 (1.10–1.72) 0.005 1.76 (1.39–2.24) <0.001 
Postoperative biomarkers 
CEA 440 1.24 (1.14–1.34) <0.001 1.33 (1.22–1.46) <0.001 
CA19-9 436 1.12 (1.04–1.20) 0.002 1.22 (1.13–1.31) <0.001 
YKL-40 413 1.21 (1.09–1.34) <0.001 1.26 (1.13–1.41) <0.001 
IL-6 413 1.11 (1.01–1.23) 0.033 1.13 (1.02–1.26) 0.022 
CRP 434 1.07 (0.99–1.15) 0.075 1.11 (1.02–1.20) 0.011 
0 elevated 137 Reference  Reference  
1 elevated 99/403 1.18 (0.87–1.62) 0.290 1.03 (0.72–1.47) 0.882 
2 elevated 106/403 1.41 (1.05–1.91) 0.023 1.57 (1.13–2.17) 0.007 
3 elevated 48/403 1.98 (1.37–2.86) <0.001 2.42 (1.64–3.56) <0.001 
4 elevated 10/403 2.94 (1.48–5.86) 0.002 4.45 (2.21–8.96) <0.001 
5 elevated 3/403 3.67 (1.16–11.7) 0.028 10.2 (3.16–32.9) <0.001 
0–1 elevated 236/403 Reference  Reference  





Table 13. Study II: Results of the multivariate Cox regression analyses in relation to relapse-
free and overall survival. Biomarkers are presented as log2-transformed continuous 
variables. 
 n Relapse-free survival Overall survival 
HR (95% CI) p-value HR (95% CI) p-value 
Preoperative biomarkers 
CEA 440 1.00 (0.93–1.07) 0.952 1.02 (0.95–1.09) 0.602 
CA19-9 437 1.12 (1.06–1.19) <0.001 1.13 (1.06–1.20) <0.001 
YKL-40 413 1.08 (0.96–1.22) 0.212 1.19 (1.04–1.35) 0.010 
IL-6 413 1.04 (0.91–1.18) 0.566 1.03 (0.90–1.18) 0.685 
CRP 429 1.03 (0.88–1.20) 0.756 0.91 (0.77–1.06) 0.215 
0 elevated 111/399 Reference  Reference  
1 elevated 113/399 0.81 (0.58–1.12) 0.202 0.82 (0.57–1.18) 0.284 
2 elevated 101/399 1.21 (0.87–1.68) 0.252 1.58 (1.11–2.24) 0.011 
3 elevated 44/399 1.63 (1.08–2.47) 0.021 1.60 (1.02–2.50) 0.042 
4 elevated 29/399 1.88 (1.12–3.16) 0.016 1.75 (1.01–3.04) 0.046 
5 elevated 1/399 3.60 (0.48–26.8) 0.211 2.90 (0.39–21.7) 0.299 
0–1 elevated 224/399 Reference  Reference  
2–5 elevated 175/399 1.40 (1.11–1.78) 0.005 1.71 (1.33–2.21) <0.001 
Postoperative biomarkers 
CEA 440 1.17 (1.07–1.29) <0.001 1.24 (1.12–1.36) <0.001 
CA19-9 436 1.09 (1.01–1.17) 0.029 1.17 (1.08–1.28) <0.001 
YKL-40 413 1.06 (0.94–1.19) 0.323 1.10 (0.97–1.24) 0.131 
IL-6 413 0.98 (0.87–1.11) 0.755 0.95 (0.83–1.09) 0.498 
CRP 434 1.02 (0.92–1.12) 0.741 1.09 (0.99–1.20) 0.096 
0 elevated 137 Reference  Reference  
1 elevated 99/403 1.00 (0.73–1.38) 0.993 0.88 (0.61–1.27) 0.488 
2 elevated 106/403 1.30 (0.95–1.78) 0.102 1.40 (0.99–1.97) 0.055 
3 elevated 48/403 1.84 (1.25–2.71) 0.002 2.33 (1.56–3.48) <0.001 
4 elevated 10/403 2.50 (1.22–5.12) 0.012 4.42 (2.16–9.05) <0.001 
5 elevated 3/403 3.14 (0.97–10.1) 0.055 8.91 (2.71–29.2) <0.001 
0–1 elevated 236/403 Reference  Reference  
2–5 elevated 167/403 1.57 (1.24–1.98) <0.001 1.84 (1.43–2.37) <0.001 
Clinical variables included in the multivariate analyses: age; gender; location of the primary colorectal 
tumor; type of liver metastases (synchronous/metachronous); type of liver resection (minor/major); 
the number and size of the liver metastases; and the resection margins (R0/1/2). 
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Figure 8. Study II: Kaplan-Meier curves of postoperative YKL-40, IL-6, CRP, CEA, and CA19-9 
in serum showing the difference between 0–1 and 2–5 elevated biomarkers in relation to    







4.1.5 MMP-8, MMP-9, MPO and survival (III) 
In Kaplan-Meier log-rank and Cox regression analyses (p-values from the log-rank tests 
presented here), both elevated and low serum concentrations of MMP-8 (≤29.6 and >76.2 
ng/ml) before liver resection associated with poor OS (p=0.023). This was especially obvious 
among males (OS: p=0.026), in synchronous disease (OS: p=0.051), and among patients who 
had received neoadjuvant chemotherapy before liver resection (DFS: p=0.026; OS: p=0.043). 
Preoperatively high MMP-8 (>76.2 ng/ml), but not low, associated with worse survival 
among over 65-year-old patients (OS: p=0.005) (Figure 9 A) and among patients with 
primary colon tumors (DFS: p=0.020; OS: p=0.002).  
Postoperative MMP-8 was not prognostic in the whole patient cohort, but intermediate and 
high values (both >20.8 ng/ml) associated with impaired prognosis among over 65-year-old 
patients (OS: p=0.045), in colon cancer (OS: p=0.020), and in synchronous disease (DFS: 
p=0.020; OS: p=0.002). 
 
The serum values of MMP-9 were not prognostic in the whole patient cohort, but 
postoperatively elevated values (>77.7 ng/ml) associated with poor survival among over 65-
year-old patients (DFS: p=0.003; OS: p<0.001) (Figure 9 B). In other subgroups of patients, no 
statistically significant associations were found.  
 
Preoperatively elevated MPO (>218.6 ng/ml) associated with improved DFS and OS in the 
whole patient cohort (DFS: p<0.001; OS: p=0.014) (Figure 10), and this was most evident 
among females (DFS: p=0.001; OS: p=0.013), under 65-year-old patients (DFS: p<0.001; OS: 
p=0.004), and those with synchronous liver metastases (DFS: p=0.001; OS: p=0.005). In 
addition, among patients who had received neoadjuvant chemotherapy, low preoperative 
MPO associated with poor prognosis (DFS: p<0.001; OS: p=0.020), but the association was 
non-significant among those who had not received neoadjuvant treatment.  
Postoperatively elevated MPO (>218.6 ng/ml) indicated poor survival only among over 65-
year-old patients (OS: p=0.037).  
 
Neither postoperative increase nor decrease in the serum concentrations of these 





Figure 9.   Study III: A) Preoperative serum concentrations of MMP-8, and B) postoperative 
serum concentrations of MMP-9 in over 65-year-old patients in relation to 10-year overall 








Figure 10. Study III: Preoperative serum concentrations of MPO in relation to A) 5-year 








4.2 Tumor tissue specimens and survival (III and IV) 
 
The results of the univariate Cox regression analyses in relation to disease-free and overall 
survival are shown in Table 14. 
 
 
4.2.1 MMP-2, MMP-8, MMP-9 and survival (III) 
In the survival analyses (p-values of the log-rank tests presented here), the expression of 
MMP-2 and MMP-8 in the primary colorectal tumors or the liver metastases did not 
associate with DFS or OS, when the whole patient cohort was studied. However, low 
expression of MMP-2 in the liver metastases indicated worse DFS among female patients 
(p=0.032), and high expression of MMP-8 in the liver metastases worse OS in patients with 
primary colon tumors (p=0.046). In addition, low MMP-8 expression in the primary tumors 
associated with impaired prognosis (DFS: p=0.005; OS: p=0.097) among patients who had 
not received neoadjuvant chemotherapy before liver resection (n=40/111; 36.0%), while no 
association was found among those who had (n=66/111; 59.5%).  
High expression of MMP-9 in the primary colorectal tumors associated with better DFS 
(p=0.010) and also with better OS nearly significantly (p=0.067) (Figure 11). The association 
was most obvious among female patients (DFS: p=0.005; OS: p=0.014), in patients with 
primary colon tumors (DFS: p=0.011; OS: p=0.037), in metachronous disease (DFS: p=0.005; 
OS: p=0.032), and among patients who had not received neoadjuvant therapy (DFS: p=0.006; 
OS: p=0.062). Among those who had received neoadjuvant therapy, no difference between 
the low and high expression groups was observed. The expression of MMP-9 in the liver 
metastases did not associate with either DFS or OS. 
 
 
4.2.2 TKTL1 and survival (IV) 
The expression of TKTL1 did not associate with DFS or OS across the entire patient cohort 
(N=111). However, in patients with synchronous liver metastases (n=66/111; 59.5%), high 
TKTL1 expression in the primary colorectal tumors associated with shorter DFS compared to 
patients with low TKTL1 expression (HR 2.14, p=0.030). Concerning TKTL1 expression in the 
liver metastases, no statistically significant associations were found, but only 12% (2/17) of 
the patients with high expression were alive without recurrence three years after liver 
resection compared to 30% (10/33) of those with low expression.  
In metachronous disease (n=45/111; 40.5%), patients with high TKTL1 expression in the 
primary tumors had a better DFS compared to those with low expression, even though the 
finding was not statistically significant (HR 0.41, 95% CI 0.15–1.13, p=0.084). In addition, 70% 
(7/10) of the patients with high expression in the liver metastases were alive without 
recurrence after three years compared to 32% (9/28) of those with low expression. 
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In the subgroups of patients with high TKTL1 expression in either the primary tumors (n=25) 
or the liver metastases (n=27), patients with synchronous metastases had a worse DFS 
compared to those with metachronous ones (primary tumors: HR 4.66, 95% CI 1.57–13.8, 
p=0.005; liver metastases: HR 3.55, 95% CI 1.23–10.2, p=0.019) (Figure 12). For the patients 
with high expression of TKTL1 in the primary tumors, DFS at three years after liver resection 
was only 7% (1/14) in synchronous disease compared to 73% (8/11) in metachronous 
disease, and for those with high expression in the liver metastases, 12% (2/17) in 
synchronous compared to 70% (7/10) in metachronous disease.  
 
 
Table 14. Studies III and IV: Results of the univariate Cox regression analysis of the biomarker 
expressions in tumor tissue in relation to disease-free and overall survival. Low expression 
groups are used as a reference. Table contains previously unpublished data (R.P. 2020). 
Study Biomarker Score n Disease-free survival Overall survival 
HR (95% CI) p-value HR (95% CI) p-value 
Biomarkers in colorectal tumor tissue 
III MMP-2 High 71/81 1.03 (0.49–2.18) 0.929 0.79 (0.37–1.69) 0.549 
III MMP-8 High 43/81 0.69 (0.42–1.14) 0.144 0.74 (0.43–1.28) 0.281 
III MMP-9 High 30/81 0.50 (0.29–0.86) 0.012 0.59 (0.33–1.05) 0.070 
IV TKTL1 High 25/81 1.00 (0.58–1.73) 0.998 0.90 (0.50–1.62) 0.729 
Biomarkers in liver metastasis tissue 
III MMP-2 High 40/88 0.77 (0.48–1.23) 0.271 0.75 (0.45–1.25) 0.267 
III MMP-8 High 33/88 1.21 (0.75–1.95) 0.431 1.29 (0.77–2.14) 0.334 
III MMP-9 High 20/88 0.99 (0.57–1.71) 0.969 0.79 (0.43–1.45) 0.442 
IV TKTL1 High 27/89 1.03 (0.62–1.72) 0.897 1.12 (0.65–1.92) 0.686 




Figure 11. Study III: The expression of MMP-9 in primary colorectal tumors in relation to      







Figure 12. Study IV: Patients with high expression of TKTL1 (score 3) in A) colorectal tumors, 
and B) liver metastases. Kaplan-Meier curves presenting the difference in 5-year disease-free 










In this thesis, the prognostic value of 12 different biomarkers was evaluated in patients 
undergoing curative-intent liver resection for colorectal metastases. Of these, 10 were 
determined in serum or plasma, and four in tissue specimens of the primary colorectal 
tumors and the liver metastases. Altogether 442 patients were included in the four studies.  
The results confirmed the prognostic value of serum CEA and CA19-9, but also identified 
their limitations. Novel information was obtained concerning the inflammatory serum 
biomarkers YKL-40 and IL-6 combined with CRP. A biomarker panel comprising these three 
biomarkers together with CEA and CA19-9 was presented as a clinically useful tool for 
estimating the risk of relapse and death after liver resection.  
Serum MPO was identified as a prognostic biomarker in metastatic CRC for the first time. In 
addition, valuable new information about the concentrations of MMP-8 and MMP-9 in 
serum as well as the expressions of MMP-2, MMP-8, MMP-9, and TKTL1 in tumor tissue was 
obtained, and differences in their prognostic significance depending on the clinical 
characteristics of the patients were observed. All the investigated biomarkers were shown to 
have some prognostic value in CRC with resectable liver metastases.  
 
 
1. CEA and CA19-9 (I and II) 
 
In this thesis, elevated CEA (>5.0 µg/l) in serum associated with shorter DFS/RFS and OS, 
when measured three months after liver resection. Preoperatively elevated values 
associated only with shorter OS.  
 
CEA is produced by tumor cells in several malignancies (Carpelan-Holmström et al., 1995, 
Molina et al., 2008, Shimada et al., 2014, Uehara et al., 2008, Zhang et al., 2018b), which 
leads to the assumption that any increase above the normal serum levels might be  
indicative of existing cancer in the body. However, there are various confounding factors – 
such as smoking and non-neoplastic diseases – that also affect the serum levels (Alexander 
et al., 1976, Hao et al., 2019). In our studies, all patients had diagnosed metastatic colorectal 
cancer, which decreases the likelihood of CEA increase due to non-malignant reasons.  
 
The fact that the elevated levels of CEA before liver resection only associated with overall 
survival seems logical, as they reflect the already-existing liver metastases, which were then 
resected. In a previous study by Kawahara et al. (Kawahara et al., 2018), however, elevated 
preoperative CEA levels were indicative of future recurrence. This is contradictory to our 
results, but the difference may be due to distinct cut-off levels. Kawahara et al. used a cut-
off level of 50.0 µg/l, which is significantly higher than that of 5.0 µg/l used in the studies 
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presented here. It seems possible that identifying the patients at a high risk of postoperative 
recurrence would require a higher cut point for preoperative CEA.  
The postoperative values most probably reflect either residual or newly formed cancer, and 
thus, have a direct association with prognosis. Earlier, elevated CEA within one month after 
liver resection has been found to predict rapid recurrence (Takamoto et al., 2016), and 
postoperative increase has also associated with recurrence during the years following liver 
resection (Hara et al., 2013). Our results are in line with these, as nearly all patients with 
elevated postoperative CEA experienced recurrence, and most of the recurrences were 
detected within three years after resection.  
The dilemma with CEA is that only 30–40% of the CRC tumors are reported to produce it 
(Saito et al., 2018, Thomsen et al., 2018). In this thesis, CEA was elevated preoperatively in 
50.2% (222/442) of the patients, although all of them had diagnosed metastases at that 
point. In study I, the patients who had a normal CEA level postoperatively were found to 
develop recurrence later than those with elevated levels. The connection between elevated 
CEA seems to be in direct connection with existing cancer, with or without other clinical 
findings, but normal CEA after liver resection does not exclude recurrence at a later time. 
 
Interestingly, both pre- and postoperatively elevated levels of CA19-9 associated with 
shorter DFS/RFS and OS, although the association between the preoperative values and RFS 
was only found in study II. Among patients with normal CEA pre- or postoperatively, CA19-9 
did not provide any additional prognostic information. However, it should be noted that 
preoperatively elevated CEA was only mildly prognostic in itself, and thus, preoperative 
CA19-9 should be evaluated independently. Approximately one-third of all patients had a 
CA19-9 level of >26 kU/l before liver resection, and the elevated values indicated an 
increased risk of early recurrence and death. Based on the results presented in studies I and 
II, CA19-9 is an important prognostic biomarker, when measured before liver resection. 
Postoperatively, however, CEA seems to be more useful than CA19-9 for most patients.  
 
Based on the results of this thesis, CEA is a valuable prognostic biomarker after liver 
resection, but it should be measured regularly in order to detect recurrence. More than 50% 
of all patients included in this study had elevated levels before liver resection as a sign of 
CEA-producing carcinomas, and postoperatively increased values indicated recurrence with 
high accuracy. Thus, any postoperative increase should lead to further examinations and 
treatment. CEA is currently the only biomarker recommended to be measured regularly in 
the follow-up of CRC (Argiles et al., 2020), and our findings confirm its usefulness. However, 
in patients who do not have elevated CEA levels, other biomarkers could be considered 
instead.  
In the future, higher cut-off levels for CEA could be tested before liver resection. Based on 
earlier publications (Kawahara et al., 2018, Bredt and Rachid, 2014), it seems possible that in 
case of existing liver metastases, the prognostic significance of preoperative CEA would be 
stronger with cut-off levels higher than the routinely used 5.0 µg/l.  
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Quite surprisingly, CA19-9 seemed have more prognostic significance than CEA, when 
measured before liver resection. Instead, postoperatively its additional value compared to 
CEA remained marginal. CA19-9 is currently not recommended for the routine follow-up of 
CRC (Duffy et al., 2014), but our results suggest that it is a promising biomarker for the 
evaluation of future prognosis before proceeding to liver resection.   
 
An additional aspect to be considered is the individual variation in the biomarker levels. 
Changes in the concentrations of CEA and CA19-9 within reference limits in consecutive 
samplings should also be studied, as increase or decrease might reveal recurrent disease 
among some individuals, even though the concentrations remained normal according to the 
cut-off limits.  
 
At the Helsinki University Hospital, both CEA and CA19-9 are measured before every control 
appointment at the department of oncology after the operation on the primary colorectal 
tumor or the liver metastases. In case these biomarkers have not been elevated despite of 
metastatic disease, using other biomarkers instead should be considered. In addition, the 
significance of increasing concentrations within the reference limits should be noted, as it is 
possible that they reflect disease progression. 
 
 
2. HCGβ and TATI (I) 
 
Both hCGβ and TATI are promising biomarkers in cancer, and there are several studies on 
their prognostic significance in CRC (Birgisson et al., 2012, Gaber et al., 2010, Louhimo et al., 
2002, Lundin et al., 2000, Lundin et al., 2001, Koskensalo et al., 2012a). We found that 
preoperatively elevated TATI in plasma (>13 µg/l) associated with poor 3-year DFS after liver 
resection, and postoperatively elevated hCGβ (>1.0 pmol/l) with poor 3-year OS. Otherwise 
no statistically significant associations were found, when all patients were included in the 
analyses.  
 
Earlier, elevated hCGβ (>2.0 pmol/l) measured before the operation on the primary 
colorectal tumor was shown to predict poor OS in a material including 204 patients with 
Dukes’ A–D disease (Louhimo et al., 2002). In a cohort of 334 CRC patients undergoing 
operation on the primary tumor, preoperatively elevated serum TATI (>15.59 µg/l) predicted 
impaired DFS and OS (Gaber et al., 2010), and preoperatively elevated hCGβ (>1.55 pmol/l) 
associated with shorter survival in a cohort of 324 patients, especially among women 
(Birgisson et al., 2012).  
The previously unpublished results presented in this thesis showed that both hCGβ and TATI 
were prognostic in specified subgroups of patients. First, elevated hCGβ after liver resection 
indicated worse survival among males and in primary rectal cancer. The association among 
men is contradictory to the results of Birgisson et al. (Birgisson et al., 2012), who found an 
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association between elevated preoperative serum hCGβ levels and shorter survival among 
women. There are several possible explanations to this difference: the patients included in 
the study of Birgisson  et al. had primary colorectal tumors instead of liver-metastatic 
disease only; the hCGβ measurements were performed using serum samples instead of 
plasma; the samples were drawn before the operation on the primary tumor and not in 
conjunction with liver resection; and the cut-off level used was 1.55 pmol/l instead of 1.0 
pmol/l. However, it seems clear that the prognostic value of hCGβ is partly dependent on 
the patient’s gender and, based on the novel findings in this thesis, possibly also on the 
location of the primary tumor.  
 
Our results concerning TATI were not as promising as the previously published ones, but 
preoperatively elevated values were found to associate with shorter DFS, especially in 
synchronous disease. A substantial difference between the earlier studies and ours is that 
our material included only patients with stage IV (Dukes’ D) disease, and 47.0% (79/168) of 
the patients had metachronous liver metastases, possibly referring to lower tumoral volume 
than in primary Dukes’ D disease. Thus, it seems possible that TATI is a potential biomarker 
in metastatic CRC with a larger tumor volume.  
 
Further analyses in a larger patient cohort and more specific subgroup analyses may give 
additional information on the prognostic significance of both hCGβ and TATI. As TATI can 
inhibit the activation of latent MMPs that contribute to cancer invasion (Moilanen et al., 
2003), their relationship is also of interest. However, in the light of the present findings, the 
prognostic value of hCGβ and TATI seems to be inferior to that of CEA and CA19-9 in CRC 
with liver metastases. 
 
 
3. YKL-40, IL-6, CRP, CEA, and CA19-9 combined (II) 
 
In study II, elevated serum concentrations of the inflammatory biomarkers YKL-40 and IL-6 
associated with shorter RFS and OS, when measured either before or after liver resection, 
and postoperatively elevated CRP indicated poor survival. However, only the association of 
preoperative YKL-40 with OS was significant in the multivariate analyses.  
The prognostic value of CEA and CA19-9 individually is discussed in the previous section 1.  
 
Interestingly, when all the five biomarkers – YKL-40, IL-6, CRP, CEA, and CA19-9 – were 
combined, 2–5 elevated biomarkers either pre- or postoperatively indicated clearly worse 
RFS and OS after liver resection. The number of patients with 2–5 elevated biomarkers was 
43.9% preoperatively and 41.4% postoperatively, accounting for a significant proportion of 
the patients.  
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In an explorative analysis, it was noted that CEA and CA19-9 seemed to be the main drivers 
of the associations between the elevated biomarkers and survival, but the risk of relapse 
increased with every additional elevated biomarker.  
 
Earlier, elevated plasma levels of YKL-40 have been shown to predict poor survival in 
patients with metastatic CRC (N=566) treated with first-line oxaliplatin-based chemotherapy 
alone or combined with cetuximab (Tarpgaard et al., 2014). The results of our study are 
similar, showing that YKL-40 is an independent predictor of poor OS in patients with 
colorectal liver metastases. Concerning CRP, elevated values (>10 mg/l) before liver 
resection were earlier found to predict poor survival in a cohort of 492 CRC patients 
undergoing liver resection (Kostner et al., 2016). In our study, preoperative CRP did not have 
prognostic significance, but the postoperative values indicated poor OS. Noteworthy, we 
used a cut-off level of 5 mg/l instead of 10 mg/l, and it is possible that also the preoperative 
values would have been prognostic with a higher cut point.  
YKL-40 has been found to promote angiogenesis in malignant tumors via the regulation of 
VEGF (Yeo et al., 2019), and it also contributes to cancer metastasis by increasing the 
migration and invasion of cancer cells (Jefri et al., 2015). IL-6 stimulates the production of 
YKL-40 and CRP in the liver (Nishikawa et al., 2008, Nielsen et al., 2011, Tanaka and 
Kishimoto, 2012). In study II, we decided to investigate YKL-40, IL-6, and CRP in combination, 
because YKL-40 is also induced by proinflammatory cytokines and other biological processes 
(Yeo et al., 2019). We also estimated that the production of CRP might be affected by the 
liver metastases.  
 
Inflammation is an established characteristic of cancer (Nasr et al., 2018, Hanahan and 
Weinberg, 2011), and our results confirm the link between systemic inflammation and 
impaired prognosis in patients with colorectal liver metastases. A biomarker panel including 
the inflammatory biomarkers YKL-40, IL-6, and CRP and the cancer biomarkers CEA and 
CA19-9 could be used to identify the patients at a high risk of relapse already before liver 
resection. However, the role of IL-6 and CRP in this panel seems to be inferior to that of the 





4. MMP-8, MMP-9, and MPO in serum (III) 
 
MMP-8 and MMP-9 are promising new prognostic biomarkers in gastrointestinal 
malignancies, and their expressions in tumor tissue specimens and concentrations in serum 
have been actively investigated in the last years. Earlier, elevated serum levels of MMP-8 
have been associated with impaired prognosis in CRC (Böckelman et al., 2018, Sirniö et al., 
2018, Väyrynen et al., 2012). However, no studies concentrating on the prognostic 
significance of MMP-8 or MMP-9 in a purely metastatic setting have been published 
previously.  
Serum MPO, on the other hand, has not been studied in metastatic CRC earlier, and in Study 
III, novel data on its prognostic significance was obtained.  
 
In our patient cohort, both preoperatively low and high serum concentrations of MMP-8 
indicated shorter OS, which corresponds to the results of a study by Laitinen et al. on MMP-8 
in gastric cancer (Laitinen et al., 2018). It is worth mentioning that the pre- and 
postoperatively elevated serum values of MMP-8 associated with shorter survival especially 
among over 65-year-old patients and among those with primary colon tumors, and 
postoperatively intermediate and high values of MMP-8 in the same subgroups as well as in 
synchronous disease. Postoperatively elevated serum MMP-9 associated with poor survival 
only among over 65-year-old patients.  
MMP-8 seems to have more prognostic value in primary colon cancer rather than rectal 
cancer, and the significance of both MMP-8 and MMP-9 appears to be dependent on the 
patients’ clinical characteristics, especially age. MMPs can promote immune responses 
(Egeblad and Werb, 2002), and elevated levels of MMP-8 have been observed in several 
inflammatory conditions (Lauhio et al., 2016). Thus, the stronger prognostic value observed 
among elderly patients may be related to immune responses that become weaker with age. 
It is possible that the negative prognostic value of MMP-8 and MMP-9 is compensated by 
stronger immune responses among younger patients, which would explain why no 
association with prognosis was found among them.  
 
One factor to be taken into consideration is that the cut-off levels used in the studies on 
serum MMP-8 in CRC have varied. In Study III of this thesis, the ROC curve analyses did not 
provide any statistically significant results, and thus, we used the tertiles of the pre- and 
postoperative serum concentrations as cut points. In previous studies, at least the cut-off 
levels of 60.0, 63.4, and 100.0 ng/ml have been used (Böckelman et al., 2018, Väyrynen et 
al., 2012, Sirniö et al., 2018). In addition, the methods used in the serum determinations may 
affect the results, but the measurements in the above-mentioned studies were performed 
congruently (Mauramo et al., 2018). Thus, an optimal cut-off level for prognostic significance 




MPO is an interesting biomarker, and no previous studies have been published concerning 
the prognostic value of its serum concentrations in CRC. However, elevated serum values 
have been associated with absence of lymphovascular invasion in breast cancer (Coelho et 
al., 2014), and high infiltration of MPO-positive inflammatory cells have signified improved 
prognosis in both breast cancer (Zeindler et al., 2019) and CRC (Droeser et al., 2013).  
In our patient cohort, elevated preoperative serum concentrations associated with 
significantly improved prognosis after liver resection and, correspondingly, low 
concentrations indicated poor prognosis. The positive prognostic value was most significant 
among women, under 65-year-old patients, and in patients with synchronous liver 
metastases. The role of the postoperative concentrations remained controversial, as high 
values associated with impaired prognosis and only in over 65-year-old patients. On the 
other hand, this association among elderly patients was similar to that found concerning 
serum MMP-8 and MMP-9.  
 
These results refer to a protective role of MPO in metastatic CRC. What makes this finding 
interesting is that MPO is known to catalyze the production of the pathogenic acid HOCl 
(Gomez-Mejiba et al., 2010) and to oxidatively activate proMMP-8 and -9 (Saari et al., 1990), 
which contribute to tumor invasion. On the other hand, MPO is needed for the proper 
functioning of the immune responses (Parry et al., 1981) that have importance in 
suppressing cancer metastasis. Thus, the prognostic value of serum MPO may reflect the 
immune defense mechanisms against cancer.  
 
Another aspect to be speculated on is the strong association observed in women, which 
could refer to hormonal regulation, possibly via estrogen. Low levels of estrogen have been 
linked to increased activity of MPO in experimental menopause (Pósa et al., 2015) and, in 
theory, the positive prognostic value of MPO in women might signify lower estrogen levels in 
those patients, and thus, less aggressive disease. In men, this difference was probably not 
observed because of generally lower levels of estrogen.  
It is also worth mentioning that preoperatively low MPO indicated poor survival among 
patients who received neoadjuvant chemotherapy before liver resection, while no difference 
in survival was observed among those who did not receive neoadjuvant treatment. Thus, 
MPO may also reflect response to treatment, possibly via immunological mechanisms.  
 
Earlier, Linkov et al. observed that the serum levels of MMP-8, MMP-9, and MPO are 
individual (Linkov et al., 2009), suggesting that knowing the baseline for each patient might 
be required in order to use these biomarkers as a prognostic tool in CRC. It is probable that 
the normal levels differ with age in healthy individuals the same way as those of several 
tumor markers (Lopez et al., 1996), even though that was not confirmed in the study by 




In conclusion, MMP-8, MMP-9, and MPO are potential prognostic biomarkers in CRC with 
liver metastases. However, their prognostic significance seems to depend on the patients’ 
clinical characteristics, such as gender and age, and further knowledge of their biological 
characteristics is needed before they can be adapted to clinical use.  
Especially MPO is a biomarker of interest, since its elevated serum levels were shown to 
associate with improved prognosis. Thus, high levels may refer to stronger anticancer 
immune responses. In addition, a possible link with hormonal regulation mechanisms was 
noted, as the prognostic value of MPO was significant especially in women. Among patients 
receiving neoadjuvant treatment before liver resection, low preoperative MPO indicated 
early postoperative recurrence, suggesting that those patients might benefit from more 
efficient perioperative chemotherapy.  
 
 
5. MMP-2, MMP-8, and MMP-9 in tumor tissue (III) 
 
In study III, we found that high expression of MMP-9 in the primary colorectal tumors 
associated with a significantly improved prognosis after liver resection compared to low 
expression. The association was stronger in patients with metachronous liver metastases 
than in those with synchronous metastases, that is, in patients with no existing liver 
metastases at the time of the operation on the primary tumor. This finding is similar to that 
concerning the prognostic value of TKTL1 in study IV.  
 
In addition, the expression of MMP-9 in the primary tumors was lower in synchronous than 
in metachronous disease. Previously, Takeha et al. found that the number of MMP-9-
positive cells along colorectal tumors’ invasive margin was significantly smaller in patients 
with liver metastases compared to those without metastases (Takeha et al., 1997). These 
findings suggest that the expression pattern changes depending on the stage of the disease. 
It can be speculated that low expression of MMP-9 in the primary colorectal tumors reflects 
either already existing (synchronous) or shortly developing (metachronous) liver metastases, 
and thus, worse prognosis.  
 
The expression of MMP-9 in the primary tumors was also a stronger prognostic factor 
among women than among men, and among patients with primary colon rather than rectal 
cancer. The variance in the prognostic significance according to the exact location of the 
primary tumor is presumable, as CRCs originating from different parts of the colon or rectum 
are currently classified as different types of disease with divergent prognoses (Loree et al., 
2018, Shida et al., 2020). The association in women, on the other hand, has not been 
observed before, and it raises speculation about a possible link with hormonal regulation, 
similarly as with serum MPO. Estrogen is known to promote tumorigenesis (Heijmans et al., 
2014), and stimulation of estrogen receptor α (ERα) has been shown to induce the 
upregulation of MMP-9 (Ahmad et al., 2018). It can be hypothesized that estrogen levels are 
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higher in women than in men, leading to the release of MMP-9 from inside the tumor cells 
into the ECM via stimulation of the estrogen receptors – observed as a low expression in the 
tumor cells – and thus, impaired prognosis.  
 
Somewhat surprisingly, the expressions of MMP-2 and MMP-8 in the primary colorectal 
tumors did not associate with prognosis. In addition, the expressions of all three biomarkers 
– MMP-2, -8, and -9 – in the liver metastases were not prognostic, except for an association 
between low MMP-2 expression and shorter DFS in women, and that between high MMP-8 
expression and shorter OS among patients with primary colon cancer.  
Altogether 59.5% of the patients included in Study III received neoadjuvant chemotherapy 
before liver resection, and it seems possible that it affects the expression and prognostic 
significance of the investigated MMPs in the liver metastases. Indeed, when only the 
patients who did not receive neoadjuvant chemotherapy were included in the analyses, it 
was found that low expression of both MMP-8 and MMP-9 in the primary tumors associated 
with worse DFS after liver resection, while no difference was observed between the low and 
high expression groups among patients who did receive neoadjuvant therapy. In the liver 
metastases, some differences were also observed, but they remained non-significant.  
It is also worth mentioning that there was no correlation between the expressions of MMP-
2, MMP-8, and MMP-9 in the primary tumors and the liver metastases, and only the 
expression of MMP-8 in the liver metastases correlated with the serum concentrations of 
the corresponding biomarker. Thus, it seems that there is variation in the tissue expression 
of these biomarkers between the primary tumors and the liver metastases, and at least 
serum MMP-9 may be mainly produced by extratumoral cells or tissues.  
 
As a conclusion, high expression of MMP-9 in the primary colorectal tumors indicated 
improved prognosis after liver resection, especially among women and in patients with 
primary colon cancer. High expression in the primary tumors was also prognostic of better 
DFS and OS in patients with metachronous liver metastases. Hence, liver resection seems to 
be especially effective among patients with high MMP-9 expression in the primary tumors, 
but among those with low expression, efficient perioperative chemotherapy and more 
intensive follow-up after resection may be beneficial. The possible connection with 
hormonal regulation should be examined further. 
MMP-2 and MMP-8 in the primary colorectal tumors were not prognostic in the whole 
patient cohort, but it seems that the patients with low MMP-8 expression may also benefit 
from neoadjuvant chemotherapy before liver resection. The expression in the liver 
metastases was neither indicative of prognosis, which may be due to the neoadjuvant 





6. TKTL1 (IV) 
 
In patients with synchronous liver metastases, high TKTL1 expression in both the primary 
colorectal tumors and the liver metastases associated with poor prognosis. By contrast, in 
patients with metachronous metastases, high expression in the primary tumors and the 
metastases indicated better prognosis.  
In previous studies, high TKTL1 expression has been shown to predict poor prognosis in lung 
and cervix cancer (Kayser et al., 2011, Chen et al., 2009), oral squamous cancer (Grimm et 
al., 2014), ocular adnexal tumors (Lange et al., 2012), and also in locally advanced rectal 
cancer (Schwaab et al., 2011). In a material of 733 CRC patients, of whom 22.5% (165/733) 
had a stage IV disease, high TKTL1 expression in primary colorectal tumors associated with 
poor disease-specific survival (Ahopelto et al., 2016). Our results in a cohort comprising only 
patients with resectable colorectal liver metastases offer a new dimension to this biomarker, 
as high expression in the primary tumors and the liver metastases indicated improved 
prognosis in patients with metachronous metastases.  
 
A possible explanation for our findings could be that synchronous and metachronous CRC 
are two different types of disease. TKTL1 is suggested to catalyze the non-oxidative part of 
the PPP, enabling the tumor cells to consume glucose in the absence of oxygen and to 
produce lactate, consequently enhancing the invasiveness of cancer (Langbein et al., 2006). 
In a study by Diaz-Moralli et al., the expression of TKTL1 in colorectal tumors was shown to 
increase progressively in disease stages I to III, but in stage IV, a strong decrease in the 
expression was observed (Diaz-Moralli et al., 2011). A similar pattern was found concerning 
the incidence of KRAS mutations, and it was speculated that the change in TKTL1 expression 
could be linked to the mutational status, and that RAS mutations might activate TKTL1. 
 
Based on the results of our study, we argued that high expression of TKTL1 increases the 
invasiveness and metastatic ability of CRC, but in the patients with high expression in the 
primary tumors and no existing liver metastases (metachronous setting), there may be some 
other factors that strongly diminish the cancer’s metastatic potential. As such, it remains 
unclear whether a high expression in metachronous CRC truly indicates a better prognosis or 
if it reflects other, yet unknown characteristics that reduce the invasiveness of the disease. 
KRAS mutational status might provide important further information concerning this. 
However, among patients with synchronous liver metastases and high TKTL1 expression in 
the primary colorectal tumors, more aggressive chemotherapy could be considered in 





7. STRENGTHS AND LIMITATIONS 
 
The strengths of the four studies presented here are the long follow-up period of up to 20 
years as well as comprehensive and reliable follow-up data. The patient material was 
uniform, consisting solely of patients who had liver metastases of CRC operated on at a 
single institute. In study II, the number of patients was exceptionally large. In studies III and 
IV, on the other hand, the study material was unique, consisting of tumor tissue samples of 
both the primary colorectal tumors and the liver metastases in addition to serum samples 
drawn before and after liver resection.  
A limitation of the studies is the missing information concerning the patients’ RAS and BRAF 
mutation status as well as the MSI/MMR status. These were not routinely analyzed at the 
Helsinki University Hospital prior to years 2013 and 2018, respectively. In study II, a 
validation cohort would have further increased the value of the findings. In addition, the 
diurnal variation of IL-6 was not considered, which may confound the results. In studies III 
and IV, the major limitation was the quite small size of the patient cohort, which restricted 
the subgroup analyses and decreased the strength of the results. However, the statistically 
significant findings most probably are reliable, since they were obvious despite of the size of 
the cohort.  
In addition, it can be speculated that the advances in the surgical techniques and the 
oncological treatments over the past couple of decades may partly confound the results 
presented here. Disease-free and overall survival of the patients with metastatic CRC have 
improved significantly, and it can be assumed that the patients who underwent liver 
resection later during the study period of this thesis had a better prognosis to start with than 
those who underwent resection in the early years. The long study inclusion period can also 
confound the results concerning the tissue biomarker expressions, as the age of the tissue 
specimens may affect the quality of the immunohistochemical stainings. However, no 







Based on the results of the four studies and the previously unpublished results presented in 
this thesis, the following is concluded: 
 
 
1. CEA is a useful prognostic biomarker for approximately half of the patients following 
liver resection for colorectal metastases. However, a notable proportion of patients 
do not have elevated serum levels despite of metastatic disease, and some of those 
patients may benefit from measuring CA19-9, especially preoperatively. For patients 
who have normal CEA and/or CA19-9 levels, other biomarkers might be tested and 
considered instead in the follow-up after liver resection.  
 
2. The prognostic value of hCGβ and TATI was found to be inferior to that of CEA and 
CA19-9, but they may identify some patients at a high risk of recurrence or death 
after liver resection. 
 
3. A biomarker panel comprising YKL-40, IL-6, CRP, CEA, and CA19-9 could be used to 
identify the patients with a poor prognosis after liver resection. Two or more 
elevated biomarkers before or after resection indicate future recurrence and shorter 
survival. With this biomarker panel, the prognosis might be assessed already before 
liver resection, and the surgical and oncological treatments adjusted accordingly.  
 
4. Elevated preoperative serum levels of MPO associate with improved prognosis, 
especially among women, under 65-year-old patients, and in patients with 
synchronous liver metastases. High expression of MMP-9 in the primary colorectal 
tumors indicates improved prognosis after liver resection, especially among women, 
in colon cancer, and in patients with metachronous liver metastases. Neoadjuvant 
chemotherapy seems to be especially beneficial for patients with low expression of 
MMP-8 and/or MMP-9 in the primary tumors, and low preoperative serum levels of 
MPO despite of neoadjuvant therapy indicate poor prognosis. The prognostic value 
of MMP-2, MMP-8, and MMP-9 in tumor tissue as well as MMP-8, MMP-9, and MPO 
in serum seems to be strongly related to the clinical characteristics of the affected 
patients, possibly via immunological and hormonal mechanisms. 
 
5. High expression of TKTL1 in the primary colorectal tumors and the liver metastases is 
a sign of poor prognosis in colorectal cancer with synchronous liver metastases, and 
more efficient treatment should be considered for those patients. On the contrary, 
high expression in the primary tumors and the liver metastases indicates better 
disease-free survival in metachronous disease. This difference may be due to stage-







Over the past years, it has become obvious that colorectal cancer is a disease with 
individually varying characteristics. The factors affecting the patients’ prognosis are diverse, 
and they include molecular, metabolic, inflammatory, and hormonal regulation mechanisms. 
The search for reliable, easily accessed, and universally valid biomarkers for the follow-up of 
both local and metastatic CRC has been intense, but by far, it has been challenging to find 
biomarkers that would be applicable to all patients.  
 
All research is based on reliable technical methods, and the results should be repeatable and 
comparable worldwide. At present, there is variation in the determination methods of 
several new serum/plasma biomarkers as well as in the interpretation of 
immunohistochemical stainings of tumor tissue samples. This causes challenges in the 
comparability of the results. The optimal methods for determining the concentrations or 
expressions of all biomarkers of interest should be established in order to produce generally 
comparable scientific data. 
 
Different inflammatory biomarkers have great prognostic potential in various malignancies, 
as inflammation contributes to cancer invasion and progression. However, there is 
fluctuation in the normal physiological serum/plasma concentrations, and it would be 
valuable to define the reference levels according to age, gender, and other potentially 
confounding factors. Subsequently, the levels could be compared to those in CRC patients 
with local and metastatic disease. In addition, consecutive samplings and measurements of 
serum/plasma biomarkers after surgical interventions or during and after oncological 
treatment might give prognostic information and help estimate the response to treatment.  
Biomarker panels including several different biomarkers, measured at the time of diagnosis 
of CRC or before liver resection, could be applied to clinical use, as they seem to have more 
prognostic value when used in combination. YKL-40, IL-6, CRP (or hsCRP), MMP-8, MMP-9, 
and MPO are promising biomarkers in this respect.  
The biomarkers’ tissue expressions in the liver metastases should be evaluated in larger 
patient cohorts with precise information about the possible neoadjuvant treatments. 
Biomarker expression in normal liver tissue outside the tumor cells might possibly provide 
novel information on the mechanisms of invasion.  
The advances in genetic testing and the adoption of liquid biopsies to clinical use are 
expected to enable more extensive research shortly. After all, understanding the regulatory 
mechanisms behind the invasion and metastasis of CRC creates the basis for all treatment. 
 
Estimating the prognosis of CRC with liver metastases already prior to liver resection is 
important, because it enables making necessary changes in the treatment plan. Hopefully, 
the biomarkers studied in this thesis will be useful in this respect. They increase our 
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